Substituted imidazo[4,5-c]cinnolin-2-one compounds as selective modulators of ATM kinase and their uses

By developing novel substituted imidazo[4,5-c]cenline-2-one compounds, the problems of AO susceptibility and brain penetration of existing ATM kinase inhibitors in humans have been solved, providing a highly effective ATM kinase inhibitor suitable for the treatment of various cancers, especially brain tumors.

CN115636833BActive Publication Date: 2024-11-29SUZHOU ZANRONG PHARMA LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202211142049.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-16
Publication Date
2024-11-29
Estimated Expiration
2039-09-16

AI Technical Summary

Technical Problem

Existing ATM kinase inhibitors exhibit high aldehyde oxidase (AO) susceptibility in humans, resulting in high clearance rates, high PK variability, and low oral bioavailability. Furthermore, they cannot penetrate brain tissue, limiting their application in the treatment of brain tumors.

Method used

Develop novel substituted imidazo[4,5-c]-cynolin-2-one compounds that do not exhibit AO susceptibility in human hepatic cytosol, have good pharmacokinetic (PK) properties, low-dose and low-dose PK variability, and can penetrate brain tissue, reducing susceptibility to hERG.

Benefits of technology

It provides an effective ATM kinase inhibitor suitable for the treatment of extracranial cancers and brain tumors, including brain tumors, with good brain penetration and toxicity characteristics, reducing the risk of hERG activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively regulate ataxia telangiectasia mutated ("ATM") kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and their salts as active ingredients, and the use of the compounds and their salts in the treatment of diseases or conditions associated with ATM (including cancer).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with application number 201980060250.5, application date September 16, 2019, and invention name “1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2-one as a selective regulator of ataxia telangiectasia mutated (ATM) kinase and its use”. Technical Field

[0002] The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively regulate ataxia telangiectasia mutated ("ATM") kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and their salts as active ingredients, and the use of the compounds and their salts in treating diseases or conditions associated with ATM (including cancer). Background Art

[0003] ATM kinase is a serine / threonine kinase named after autosomal recessive ataxia telangiectasia (AT) (Paul, TT, Annu Rev Biochem 2015, 711-38). ATM plays a central role in the repair of DNA double-strand breaks (DSBs), and if not repaired in time, it has great cytotoxicity. DSBs can be repaired through two main pathways: non-homologous end joining (NHEJ) or homologous recombination (HR). NHEJ operates throughout the cell cycle, directly resealing the two broken ends with minimal processing. In contrast, HR occurs in the S and G2 phases of the cell cycle, so a large amount of end processing (or resection) is required. This produces single-stranded DNA of the homologous copy of the intrusion locus, which is then used as a template for DNA synthesis (Clouaire, T. et al., DNA Repair (Amst) 2017, 84-91). In contrast, NHEJ is a fast process, but it is prone to errors; while HR is a slower process than NHEJ, but it is error-free. ATM repairs DSBs through HR.

[0004] Following DNA DSB, ATM is recruited by the MRE11-RAD50-NBS1 (MRN) complex that senses and initiates DNA repair. When ATM is brought to the site of DNA damage, it dissociates from an inactive homodimer into an active monomer and is catalytically activated by autophosphorylation of Ser1981 and other sites and acetylation of Lys3016. ATM then binds to the C-terminus of NBS1, a component of the MRN complex, and acts as a transducer, phosphorylating and activating other protein kinases, such as histone H2A.X (γH2A.X).

[0005] ATM is activated by DSBs, which can be induced by ionizing radiation, chemotherapeutic drugs, and PARP inhibition. Topoisomerase-I inhibitors (e.g., irinotecan, topotecan) and PARP inhibitors (e.g., olaparib) cause single-strand DNA breaks, which are converted into DSBs during replication (Choi M. et al., Mol Cancer Ther, 2016, 1781-91). Other anticancer treatments, such as ionizing radiation (IR), platinum drugs (cisplatin), and topoisomerase II inhibitors (doxorubicin, etoposide) directly induce DSBs. The combination of ATM inhibitors with chemotherapy, radiation, and PARP inhibitors makes it almost impossible for cancer cells to repair DSBs that are highly cytotoxic. Given the key role played by ATM in DSBs, ATM kinase inhibitors are expected to work synergistically with PARP or topoisomerase inhibitors or ionizing radiation in cancer treatment.

[0006] A number of structurally distinct compounds have been reported that show activity against ATM kinase. WO2015 / 170081, WO2017 / 046216 and WO2017 / 076895 (Astrazeneca AB) report imidazo[4,5-c]quinolin-2-one compounds as selective modulators of ATM kinase, among which AZD0156 and AZD1390 are phase 1 clinically effective ATM inhibitors:

[0007]

[0008] However, both compounds are highly active aldehyde oxidase (AO) substrates. AO is highly expressed in humans and monkeys, but not in dogs, and is expressed at low levels in rodents. Compounds metabolized by AO show high clearance, high PK variability, and low oral bioavailability in humans (Garattini, E. et al., Expert Opin Drug Discovery, 2013, 641-54; Zientek, M. et al., Drug MetabDispos, 2010, 1322-7). AO susceptibility can be evaluated in a human liver cytosol system. The human PK of AZD0156 was unexpectedly lower than expected (Chen et al., AACR, 2018), and a Phase 0 clinical PK study of AZD1390 was conducted before committing to a Phase 1 clinical study (NCT03215381 and NCT03423628), further suggesting that AZD0156 and AZD1390 are subject to AO-mediated metabolism. In addition, AZD0156 is unable to penetrate the brain, limiting its use in the treatment of brain tumors. AZD1390 shows hERG susceptibility and has cardiac adverse effects.

[0009] Therefore, there remains a need to develop new compounds that act on ATM kinase, preferably ones that can penetrate the brain without AO and hEGR susceptibility. Summary of the invention

[0010] Disclosed herein are novel substituted imidazo[4,5-c]cinnolin-2-one compounds that have potent ATM kinase inhibitory activity, do not show AO susceptibility in human liver cytosol, and thus have good human pharmacokinetics (PK), low doses, and low dose PK variability. Additionally, these compounds are neither human Pgp nor human BCRP substrates, exhibit good brain penetration in animals, and have favorable toxicity profiles (e.g., reduced activity against hERG). As a result, the compounds of the present application are particularly effective for treating diseases or conditions associated with ATM, including cancer (not only extracranial cancers, but also brain tumors).

[0011] In one aspect, the present disclosure provides compounds of formula (I):

[0012]

[0013] or a pharmaceutically acceptable salt thereof,

[0014] in:

[0015] R 1 is hydrogen or methyl;

[0016] R 2 is isopropyl or tetrahydropyranyl;

[0017] R 3 is hydrogen or fluorine;

[0018] R 4 , R 5 and R 6 are each independently selected from hydrogen or fluorine;

[0019] R 7 Yes-L-NR 8 R 9 , wherein L is selected from a direct bond, -(CH2) m O(CH2) n -or-CONR 10 (CH2) p -, wherein the -(CH2) m O(CH2) n -and-CONR 10 (CH2)p- is optionally substituted by one or more R 11 replace;

[0020] R 8 and R 9 Each is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, saturated or unsaturated cyclic hydrocarbon group, and saturated or unsaturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, saturated or unsaturated cyclic hydrocarbon group, and saturated or unsaturated heterocyclic group are optionally substituted by one or more R 12 replace; or

[0021] R 8 and R 9 Together with the nitrogen atom to which they are attached, they form a saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 13 replace;

[0022] R 10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl and carbon-linked saturated or unsaturated heterocyclic radicals, wherein the heterocyclic radical optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 13 replace;

[0023] R 11 is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, alkoxy and saturated or unsaturated heterocyclic radicals, the heterocyclic radicals optionally containing one or more additional heteroatoms selected from N, O and S, and optionally substituted by one or more R 13 replace;

[0024] R 12is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkenyl, alkynyl and alkoxy;

[0025] R 13 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl, nitro and -(CH2) q NR 14 R 15 The group composed of;

[0026] R 14 and R 15 are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl; or

[0027] R 14 and R 15 Together with the nitrogen atom to which they are attached, they form a saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 16 replace;

[0028] R 16 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl and nitro;

[0029] m is 0, 1, or 2;

[0030] n is an integer from 2 to 4;

[0031] p is an integer from 2 to 4; and

[0032] q is 0, 1, or 2;

[0033] The premise is that when R 2 is tetrahydropyran-3-yl and R 3 When it is hydrogen, R 7 Not -O(CH2)3N(CH3)2.

[0034] In another aspect, provided herein is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

[0035] In another aspect, provided herein is a method of treating a disease or condition associated with ATM in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0036] In another aspect, provided herein is a method of treating Huntington's disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

[0037] In another aspect, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating an ATM-related disease or disorder.

[0038] In another aspect, provided herein is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease or condition associated with ATM.

[0039] In another aspect, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease or condition associated with ATM, wherein the compound of formula (I) is administered simultaneously, separately or sequentially with radiotherapy.

[0040] In another aspect, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential administration with at least one additional anti-tumor agent. DETAILED DESCRIPTION

[0041] Reference will now be made in detail to certain embodiments of the present invention, examples of which are shown in the accompanying structures and formulas. Although the present invention will be described in conjunction with the enumerated embodiments, it should be understood that they are not intended to limit the present invention to those embodiments. On the contrary, the present invention is intended to cover all substitutions, modifications and equivalents, which may be included within the scope of the present invention defined by the claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The present invention is by no means limited to the described methods and materials. In one or more of the combined documents and similar materials, including but not limited to defined terms, term usage, described technology, etc., when different from or conflicting with the present application, the present application shall prevail.

[0042] It should be understood that certain features of the present disclosure described in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the present disclosure described in the context of a single embodiment for brevity may also be provided separately or in any suitable sub-combination.

[0043] definition

[0044] Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are conventionally as defined herein. In addition, general principles of organic chemistry as well as specific functional moieties and reactivities are described in the following references: Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987, the entire contents of each of which are incorporated herein by reference.

[0045] At various places in this disclosure, linking substituents are described. If a structure clearly requires a linking group, the Markush variable listed for that group should be understood to be a linking group. For example, if a structure requires a linking group and the Markush group definition for that variable lists "alkyl", it should be understood that "alkyl" represents a linking alkylene group.

[0046] As used herein, the term "substituted" refers to a chemical group when it is related to a chemical group having one or more hydrogen atoms removed and replaced by a substituent. As used herein, the term "substituent" has the common meaning known in the art and refers to a chemical moiety covalently attached to or fused to a parent group if appropriate. As used herein, the term "optionally substituted" or "optionally ... substituted" means that the chemical group may not have a substituent (i.e., unsubstituted) or may have one or more substituents (i.e., substituted). It should be understood that substitution on a given atom is limited by valence.

[0047] As used herein, the term “C i-j " represents a range of carbon atoms, wherein i and j are integers, and the range of carbon atoms includes two endpoints (i.e., i and j) and every integer point therebetween, wherein j is greater than i. For example, C 1-6In some embodiments, the term "C" refers to a range of 1-6 carbon atoms, including one carbon atom, two carbon atoms, three carbon atoms, four carbon atoms, five carbon atoms, and six carbon atoms. 1-12 ” means 1 to 12, especially 1 to 10, especially 1 to 8, especially 1 to 6, especially 1 to 5, especially 1 to 4, especially 1 to 3 or especially 1 to 2 carbon atoms.

[0048] As used herein, whether as part of another term or used independently, the term "alkyl" refers to a saturated straight or branched hydrocarbon chain, which may be optionally substituted independently with one or more substituents as described below. i-j "Alkyl" refers to an alkyl group having i to j carbon atoms. In some embodiments, the alkyl group contains 1 to 12 carbon atoms. In some embodiments, the alkyl group contains 1 to 11 carbon atoms. In some embodiments, the alkyl group contains 1 to 11 carbon atoms, 1 to 10 carbon atoms, 1 to 9 carbon atoms, 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl (n-propyl), 2-propyl (isopropyl), 1-butyl (n-butyl) 2-methyl-2-propyl (isobutyl), 2-butyl (sec-butyl), 2-methyl-2-propyl (tert-butyl), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, etc. “C 1-12 Examples of "alkyl" include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. 1-6 Examples of "alkyl" are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, and the like.

[0049] The alkyl group may be further substituted with substituents which independently replace one or more hydrogen atoms on one or more carbon atoms of the alkyl group. Examples of such substituents may include, but are not limited to, acyl, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carboxamido and urea), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfonyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, nitro, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, heteroalkyl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl and heteroaryl groups as described below may also be similarly substituted.

[0050] As used herein, whether as part of another term or used independently, the term "alkenyl" refers to a straight or branched hydrocarbon group having at least one carbon-carbon double bond, which may be optionally substituted independently by one or more of the substituents, including groups with "cis" and "trans" orientations, or "E" and "Z" orientations. In some embodiments, the alkenyl group comprises 2 to 12 carbon atoms. In some embodiments, the alkenyl group comprises 2 to 11 carbon atoms. In some embodiments, the alkenyl group comprises 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkenyl group comprises 2 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (ethylenyl or vinyl), propenyl, butenyl, pentenyl, 1-methyl-2butene-1-yl, 5-hexenyl, etc.

[0051] As used herein, whether as part of another term or used independently, the term "alkynyl" refers to a straight or branched hydrocarbon group having at least one carbon-carbon triple bond, which may be optionally substituted independently by one or more of the substituents. In some embodiments, the alkenyl group comprises 2 to 12 carbon atoms. In some embodiments, the alkynyl group comprises 2 to 11 carbon atoms. In some embodiments, the alkynyl group comprises 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkynyl group comprises 2 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, etc.

[0052] As used herein, whether as part of another term or used independently, the term "alkoxy" refers to an alkyl group as defined above attached to the parent molecular group through an oxygen atom. i-j "Alkoxy" means that the alkyl portion of the alkoxy has i to j carbon atoms. In some embodiments, the alkoxy contains 1 to 12 carbon atoms. In some embodiments, the alkoxy contains 1 to 11 carbon atoms. In some embodiments, the alkoxy contains 1 to 11 carbon atoms, 1 to 10 carbon atoms, 1 to 9 carbon atoms, 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. "C 1-12 Examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, neopentoxy, n-hexyloxy, and the like.

[0053] As used herein, the term "acyl" refers to a carbonyl-containing functional group, such as -C(=O)R, wherein R is hydrogen or an optionally substituted aliphatic, heteroaliphatic, heterocyclic, aryl, heteroaryl group, or is a substituted (e.g., with hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety) oxygen- or nitrogen-containing functional group (e.g., forming a carboxylic acid, ester or amide functional group). As used herein, the term "acyloxy" refers to an acyl group attached to the parent molecule through an oxygen atom.

[0054] As used herein, the term "amino" or "amine" refers to a moiety in which a nitrogen atom is covalently bonded to at least one carbon or heteroatom. "Alkylamino" includes a compound group in which nitrogen is bonded to at least one alkyl group. Examples of alkylamino include benzylamino, methylamino, ethylamino, phenethylamino, etc. "Dialkylamino" includes a group in which a nitrogen atom is bonded to at least two additional alkyl groups. Examples of dialkylamino include, but are not limited to, dimethylamino and diethylamino. "Arylamino" and "diarylamino" include groups in which nitrogen is bonded to at least one or two aryl groups, respectively. "Alkylarylamino", "alkylaminoaryl" or "arylaminoalkyl" refers to an amino group bonded to at least one alkyl group and at least one aryl group. "Alkylaminoalkyl" refers to an alkyl, alkenyl or alkynyl group bonded to a nitrogen atom, which is also bonded to an alkyl group. "Acylamino" includes a group in which nitrogen is bonded to an acyl group. Examples of acylamino include, but are not limited to, alkylcarbonylamino, arylcarbonylamino, formamido and urea.

[0055] As used herein, the term "amide" or "aminocarboxyl" refers to a compound or moiety containing a nitrogen atom bonded to the carbon of a carbonyl or thiocarbonyl group. The term includes an "alkaminocarboxy" group, which includes an alkyl, alkenyl, or alkynyl group bonded to an amino group, which is also bonded to the carbon of a carbonyl or thiocarbonyl group. It also includes an "arylaminocarboxy" group, which includes an aryl or heteroaryl moiety bonded to an amino group, which is bonded to the carbon of a carbonyl or thiocarbonyl group. The terms "alkylaminocarboxyl", "alkenylaminocarboxyl", "alkynylaminocarboxyl" and "arylaminocarboxyl" include moieties in which alkyl, alkenyl, alkynyl, and aryl moieties are each bonded to a nitrogen atom, which is in turn bonded to the carbon of a carbonyl group. Amides may be substituted with substituents such as straight-chain alkyl, branched-chain alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclic. The substituents on the amide group may be further substituted.

[0056] As used herein, whether as part of another term or used independently, the term "aryl" refers to monocyclic and polycyclic systems having a total of 5 to 20 ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 12 ring members. Examples of "aryl" include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, etc., which may carry one or more substituents. Also included within the scope of the term "aryl" as used herein are groups in which an aromatic ring is fused to one or more additional rings. In the case of a polycyclic system, although all rings may be aromatic (e.g., quinoline), only one ring needs to be aromatic (e.g., 2,3-dihydroindole). The second ring may also be fused or bridged. Examples of polycyclic aryls include, but are not limited to, benzofuranyl, indanyl, phthalimido, naphthalimido, phenanthridinyl, or tetrahydronaphthyl, etc. Aryl may be substituted by substituents as described above at one or more ring positions.

[0057] As used herein, the terms "cycloalkyl", "carbocyclyl" and "carbocycle" are interchangeable and, whether used as part of another term or independently, refer to monovalent non-aromatic, saturated or partially unsaturated monocyclic and polycyclic systems, wherein all ring atoms are carbon and contain at least three ring-forming carbon atoms. In some embodiments, the cycloalkyl may contain 3 to 12 ring-forming carbon atoms, 3 to 10 ring-forming carbon atoms, 3 to 9 ring-forming carbon atoms, 3 to 8 ring-forming carbon atoms, 3 to 7 ring-forming carbon atoms, 3 to 6 ring-forming carbon atoms, 3 to 5 ring-forming carbon atoms, 4 to 12 ring-forming carbon atoms, 4 to 10 ring-forming carbon atoms, 4 to 9 ring-forming carbon atoms, 4 to 8 ring-forming carbon atoms, 4 to 7 ring-forming carbon atoms, 4 to 6 ring-forming carbon atoms, 4 to 5 ring-forming carbon atoms. The cycloalkyl may be saturated or partially unsaturated. The cycloalkyl may be substituted. In some embodiments, the cycloalkyl group may be a saturated cyclic alkyl group. In some embodiments, the cycloalkyl group may be a partially unsaturated cyclic alkyl group containing at least one double bond or triple bond in its ring system.

[0058] In some embodiments, the cycloalkyl group can be a saturated or partially unsaturated monocyclic carbocyclic ring system, examples of which include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl.

[0059] In some embodiments, cycloalkyl can be a saturated or partially unsaturated polycyclic (for example, bicyclic and tricyclic) carbocyclic ring system, which can be arranged as a fused ring, a spirocyclic ring or a bridged ring system. As used herein, the term "fused ring" refers to a ring system with two rings sharing two adjacent atoms, the term "spirocyclic ring" refers to a ring system with two rings connected by a single common atom, and the term "bridged ring" refers to a ring system with two rings sharing three or more atoms. The example of the fused carbocyclic group includes but is not limited to naphthyl, benzopyrenyl, anthracenyl, acenaphthenyl, fluorenyl, etc. The example of spiral carbocyclic group includes but is not limited to spiral [5.5] undecyl, spiral-pentadienyl, spiral [3.6]-decyl, etc. Examples of bridged carbocyclic groups include, but are not limited to, bicyclo[1,1,1]pentenyl, bicyclo[2,2,1]heptenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonanyl, bicyclo[3.3.3]undecyl, and the like.

[0060] As used herein, the term "cyano" refers to -CN.

[0061] As used herein, the term "halo" or "halogen" refers to an atom selected from fluorine, chlorine, bromine and iodine.

[0062] As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more halogen atoms.

[0063] As used herein, the term "haloalkoxy" refers to an alkoxy group substituted with one or more halogen atoms.

[0064] As used herein, whether as part of another term or used independently, the term "heteroaryl" refers to an aryl having one or more heteroatoms in addition to a carbon atom. As used herein, the term "heteroatom" refers to nitrogen, oxygen or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of basic nitrogen. Examples of heteroaryl include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, benzofuranyl and pteridinyl. Heteroaryl also includes a group in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclic rings, wherein the base or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. In some embodiments, the term "5- to 10-membered heteroaryl" refers to a 5- to 6-membered heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur. In certain embodiments, the term "5- to 12-membered heteroaryl" refers to a 5- to 6-membered heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8- to 12-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0065] As used herein, the term "heterocycle" or "heterocyclic group" refers to a saturated or unsaturated carbocyclic group, wherein one or more ring atoms are independently selected from heteroatoms such as oxygen, sulfur, nitrogen, phosphorus, and the remaining ring atoms are carbon, wherein one or more ring atoms may be optionally substituted independently by one or more substituents. In some embodiments, the heterocyclic group is a saturated heterocyclic group. In some embodiments, the heterocyclic group is a partially unsaturated heterocyclic group with one or more double bonds in its ring system. In some embodiments, the heterocyclic group may include any oxidized form of carbon, nitrogen or sulfur and any quaternized form of basic nitrogen. "Heterocyclic group" also includes a group in which the heterocyclic group is fused to a saturated, partially unsaturated or completely unsaturated (i.e., aromatic) carbocyclic or heterocyclic ring. Where possible, the heterocyclic group may be carbon-connected or nitrogen-connected. In some embodiments, the heterocyclic ring is carbon-connected. In some embodiments, the heterocyclic ring is nitrogen-connected. For example, the group derived from pyrrole may be pyrrole-1-yl (nitrogen-connected) or pyrrole-3-yl (carbon-connected). Furthermore, groups derived from imidazole may be imidazol-1-yl (nitrogen attached) or imidazol-3-yl (carbon attached).

[0066] In some embodiments, the term "3 to 12 membered heterocyclic radical" refers to a 3 to 12 membered saturated or partially unsaturated monocyclic or polycyclic heterocyclic ring system having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur. Fused rings, spirocyclic rings and bridged ring systems are also included within the scope of this definition. Examples of monocyclic heterocyclic radicals include, but are not limited to, oxetanes, 1,1-dioxothiane pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, piperidinyl, piperazinyl, morpholinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, pyridonyl, pyrimidonyl, pyrazinonyl, pyrimidonyl, pyridonyl, pyrrolidinyl, triazinonyl (triazinonyl) etc. Examples of fused heterocyclic groups include, but are not limited to, phenyl fused rings or pyridyl fused rings, such as quinolinyl, isoquinolinyl, quinoxalinyl, quinolizinyl, quinazolinyl, azaindolizinyl, pteridinyl, chromenyl, isochromenyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, benzothienyl, benzothiazolyl, carbazolyl, phenazinyl, phenothiazinyl, phenanthridinyl, imidazo[1,2-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,3]triazolo[4,3-a]pyridinyl, etc. Examples of spiro heterocyclic groups include, but are not limited to, spiropyranyl, spirooxazinyl, etc. Examples of bridged heterocyclic groups include, but are not limited to, morpholinyl, hexamethylenetetramine, 3-azabicyclo[3.1.0]hexane, 8-azabicyclo[3.2.1]octane, 1-azabicyclo[2.2.2]octane, 1,4-diazabicyclo[2.2.2]octane (DABCO), and the like.

[0067] As used herein, the term "partially unsaturated" refers to a group that includes at least one double or triple bond. The term "partially unsaturated" is intended to include rings having multiple sites of unsaturation, but is not intended to include aromatic (ie, fully unsaturated) moieties.

[0068] As used herein, whether or not beginning with the term "optionally", the term "substituted" refers to one or more hydrogens of a specified portion being replaced by a suitable substituent. It will be understood that "substituted" or "substituted by..." includes implicit conditions, i.e., the substitution follows the allowed valence of the substituted atom, and the substitution produces a stable or chemically feasible compound, for example, it does not spontaneously undergo transformations such as rearrangement, cyclization, elimination, etc. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and may be substituted by more than one substituent selected from a specific group at one or more positions in any given structure, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that, if appropriate, the substituent itself may be substituted. Unless specifically stated as "unsubstituted", the chemical moieties mentioned herein are understood to include substituted variants. For example, mentioning an "aryl" group or moiety implicitly includes substituted and unsubstituted variants.

[0069] When a bond to a substituent is shown to span a bond connecting two atoms in a ring, then the substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom via which the substituent is bonded to the rest of the compound of a given formula, then the substituent may be bonded via any atom in that formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0070] When any variable (e.g., R i ) occurs multiple times in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is represented by 0-2 R i Partially substituted, the group may optionally be replaced by up to two R i Partially replace, and each time R i Independently selected from R i Also, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0071] Compound

[0072] The present disclosure provides novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, synthetic methods for preparing the compounds, pharmaceutical compositions containing the same, and various uses of the disclosed compounds.

[0073] In one aspect, the present invention provides compounds of formula (I):

[0074]

[0075] or a pharmaceutically acceptable salt thereof,

[0076] in:

[0077] R 1 is hydrogen or methyl;

[0078] R 2 is isopropyl or tetrahydropyranyl;

[0079] R 3 is hydrogen or fluorine;

[0080] R 4 , R 5 and R 6 are each independently selected from hydrogen or fluorine;

[0081] R 7 Yes-L-NR 8 R 9 , wherein L is selected from a direct bond, -(CH2) m O(CH2) n -or-CONR 10 (CH2) p -, wherein the -(CH2) m O(CH2) n -and-CONR 10 (CH2) p - optionally one or more R 11 replace;

[0082] R 8 and R 9 Each is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, saturated or unsaturated cyclic hydrocarbon group, and saturated or unsaturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, saturated or unsaturated cyclic hydrocarbon group, and saturated or unsaturated heterocyclic group are optionally substituted by one or more R 12 replace; or

[0083] R 8 and R 9 Together with the nitrogen atom to which they are attached, they form a saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 13 replace;

[0084] R 10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and carbon-linked saturated or unsaturated heterocyclic radicals, wherein the heterocyclic radical optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 13 replace;

[0085] R 11is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, alkoxy, and saturated or unsaturated heterocyclic radicals, the heterocyclic radicals optionally containing one or more additional heteroatoms selected from N, O and S, and optionally substituted by one or more R 13 replace;

[0086] R 12 is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkenyl, alkynyl and alkoxy;

[0087] R 13 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl, nitro and -(CH2) q NR 14 R 15 The group composed of;

[0088] R 14 and R 15 are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl; or

[0089] R 14 and R 15 Together with the nitrogen atom to which they are attached, they form a saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 16 replace;

[0090] R 16 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl and nitro;

[0091] m is 0, 1, or 2;

[0092] n is an integer from 2 to 4;

[0093] p is an integer from 2 to 4; and

[0094] q is 0, 1, or 2;

[0095] The premise is that when R 2 is tetrahydropyran-3-yl and R 3 When it is hydrogen, R 7 Not -O(CH2)3N(CH3)2.

[0096] In some embodiments, R 1 It's hydrogen.

[0097] In some embodiments, R 1 It's methyl.

[0098] In some embodiments, R 2 It is isopropyl.

[0099] In some embodiments, R 2 It is tetrahydropyranyl.

[0100] In some embodiments, R 2 It is tetrahydropyran-3-yl.

[0101] In some embodiments, R 3 It's hydrogen.

[0102] In some embodiments, R 3 It's fluorine.

[0103] In some embodiments, when R 2 is tetrahydropyran-3-yl and R 3 When it is hydrogen, then R 7 Not -O(CH2)3N(CH3)2.

[0104] In some embodiments, R 4 , R 5 and R 6 It's hydrogen.

[0105] In some embodiments, R 4 is fluorine, and R 5 and R 6 It's hydrogen.

[0106] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is optionally replaced by one or more R 11 Substituted -(CH2) m O(CH2) n -; wherein m is 0, 1 or 2, n is an integer from 2 to 4, wherein R 11 is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, alkoxy, and saturated or unsaturated heterocyclic groups.

[0107] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, R 8 and R 9 Each independently selected from optionally one or more R 12 Substituted C 1-6 Alkyl, wherein the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; R12 is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkenyl, alkynyl and alkoxy.

[0108] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, R 8 and R 9 Independently selected from methyl, ethyl, propyl or butyl, wherein the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2.

[0109] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, R 8 and R 9 is methyl, and the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2.

[0110] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, R 8 and R 9 Together with the nitrogen atom to which they are attached they form:

[0111]

[0112] Each of which is optionally replaced by one or more R 13 substituted, wherein the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; x is 1, 2, 3 or 4; y is 0, 1 or 2; z is 0, 1 or 2; R 13 Selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, alkylamino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl and nitro.

[0113] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; R 8 and R9 Together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidinyl or azabicyclo[3.1.0]hexan-3-yl radical, which is optionally substituted by one or more R 13 Substitution, where R 13 is halogen. In certain embodiments, R 13 In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; R 8 and R 9 Together with the nitrogen atom to which they are attached they form a pyrrolidinyl group which is optionally substituted by one or more fluorines.

[0114] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; R 8 and R 9 Together with the nitrogen atom to which they are attached they form a piperidinyl group which is optionally substituted by one or more fluorine groups.

[0115] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is -(CH2) m O(CH2) n -, the combination of m and n is selected from m is 0 and n is 3, or m is 1 and n is 2; R 8 and R 9 Together with the nitrogen atom to which they are attached they form an optionally fluorine-substituted azabicyclo[3.1.0]hexan-3-yl radical.

[0116] In some embodiments, when m is 0 and n is 3, R 13 Not halogen.

[0117] In some embodiments, when m is 0 and n is 3, R 13 Not azabicyclo[3.1.0]hexan-3-yl.

[0118] In some embodiments, R 7 Yes-L-NR 8 R9 , L is a direct bond, and R 8 and R 9 Together with the nitrogen atom to which they are attached they form:

[0119]

[0120] Each of which is optionally replaced by one or more R 13 substituted, wherein x is 1, 2, 3 or 4; y is 0, 1 or 2; z is 0, 1 or 2; R 13 is selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, alkylamino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl, nitro and -(CH2) q NR 14 R 15 A group consisting of; wherein q is 0, 1 or 2; R 14 and R 15 are each independently selected from the group consisting of hydrogen, alkyl and cycloalkyl, or R 14 and R 15 Together with the nitrogen atom to which they are attached, they form a saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 16 Replacement; where R 16 Selected from the group consisting of acyl, alkyl, alkenyl, alkynyl, alkoxy, amide, amino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl and nitro.

[0121] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is a direct bond, and R 8 and R 9 Together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl or piperidinyl group, which is optionally substituted by one or more R 13 Replacement; where R 13 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, amide, amino, alkylamino, aryl, cyano, cycloalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, hydroxyl, nitro and -(CH2) q NR 14 R 15 A group consisting of; wherein q is 0, 1 or 2; R 14 and R 15 Each is independently selected from the group consisting of hydrogen, alkyl and cycloalkyl.

[0122] In some embodiments, R7 Yes-L-NR 8 R 9 , L is a direct bond, and R 8 and R 9 Together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl or piperidinyl group, which is optionally substituted by one or more R 13 Replacement; where R 13 Yes - (CH2) q NR 14 R 15 ; where q is 0, 1 or 2; R 14 and R 15 Each independently selected from C 1-6 In certain embodiments, R 14 and R 15 It is methyl.

[0123] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is a direct bond, and R 8 and R 9 Together with the nitrogen atom to which they are attached they form a pyrrolidinyl group which is optionally substituted with one or more -N(CH3)2 or -(CH2)N(CH3)2.

[0124] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is a direct bond, and R 8 and R 9 Together with the nitrogen atom to which they are attached they form a piperidinyl group which is optionally substituted with one or more -N(CH3)2 or -(CH2)N(CH3)2.

[0125] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -CONR 10 (CH2) p -, R 8 and R 9 Each independently selected from optionally one or more R 12 Substituted C 1-6 Alkyl, wherein p is an integer from 2 to 4, R 10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and carbon-linked saturated or unsaturated heterocyclic groups, R 12 is selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkenyl, alkynyl and alkoxy.

[0126] In some embodiments, R 7 Yes-L-NR 8 R 9 , L is -CONR 10 (CH2) p -, R 8 and R 9 is selected from methyl, ethyl, propyl or butyl; p is 2; R 10 It's hydrogen.

[0127] In certain embodiments, R 7 Yes-L-NR 8 R 9 , L is -CONH(CH2)2-, R 8 and R 9 It's methyl.

[0128] In one aspect, the present invention provides compounds of formula (I):

[0129]

[0130] or a pharmaceutically acceptable salt thereof,

[0131] in:

[0132] R 1 It is methyl;

[0133] R 2 is isopropyl;

[0134] R 3 It is fluorine;

[0135] R 4 , R 5 and R 6 It is hydrogen;

[0136] R 7 Yes-L-NR 8 R 9 , where L, R 8 and R 9 As defined above.

[0137] In certain embodiments, L is optionally substituted with one or more R 11 Substituted -(CH2) m O(CH2) n -;

[0138] R 8 and R 9 Each independently selected from optionally one or more R 12 Substituted C 1-6 Alkyl; or

[0139] R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form

[0140]

[0141] Each of which is optionally replaced by one or more R 13 substituted, wherein x is 1, 2, 3 or 4; y is 0, 1 or 2; z is 0, 1 or 2;

[0142] R 11 It is hydrogen;

[0143] R 12 It is hydrogen;

[0144] R 13 It is a halogen;

[0145] m is 0, 1, or 2;

[0146] n is an integer from 2 to 4.

[0147] In certain embodiments, L is optionally substituted with one or more R 11 Substituted-CONR 10 (CH2) p -;

[0148] R 8 and R 9 Each independently selected from optionally one or more R 12 Substituted C 1-6 alkyl;

[0149] R 10 It is hydrogen;

[0150] R 12 is hydrogen; and

[0151] p is an integer from 2 to 4.

[0152] In certain embodiments, L is a direct bond; and

[0153] R 8 and R 9 Together with the nitrogen atom to which they are attached, they form a pyrrolidinyl or piperidinyl group, which is optionally substituted by one or more R 13 replace;

[0154] R 13 Yes - (CH2) q NR 14 R 15 ;

[0155] R 14 and R 15Each independently selected from C 1-6 Alkyl; and

[0156] q is 0, 1, or 2.

[0157] In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof selected from the group consisting of:

[0158] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0159] 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0160] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0161] 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0162] 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0163] 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0164] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0165] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(pyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0166] (R)-7-Fluoro-8-(6-((2-(3-fluoropyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0167] 7-Fluoro-8-(6-((2-(4-fluoropiperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0168] 8-(6-((2-(3-(azabicyclo[3.1.0]hexan-3-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0169] N-(2-(dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)picolinamide;

[0170] 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0171] (S)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0172] (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0173] 8-(6-(3-(3-(azabicyclo[3.1.0]hexane-3-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0174] 8-(6-(3-(dimethylamino)propoxy)-2-fluoropyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0175] 7-Fluoro-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0176] 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0177] 7-Fluoro-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0178] 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0179] 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0180] 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0181] 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0182] (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0183] 8-(6-((2-(diethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0184] 8-(6-((2-(ethyl(methyl)amino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0185] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-morpholinoethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0186] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0187] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(4-methylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0188] 8-(6-((2-(4-cyclopropylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0189] 8-(6-((2-(2-azaspiro[3.3]heptane-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0190] 8-(6-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0191] 8-(6-((2-(2-azaspiro[3.4]octan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0192] 8-(6-((2-(6-azabicyclo[3.2.0]heptane-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0193] 8-(6-(3-(diethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0194] 8-(6-(3-(ethyl(methyl)amino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0195] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-morpholinopropoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0196] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0197] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(4-methylpiperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0198] 8-(6-(3-(4-cyclopropylpiperazin-1-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0199] 8-(6-(3-(2-azaspiro[3.3]heptane-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0200] 8-(6-(3-(2-oxa-6-azaspiro[3.3]heptane-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one;

[0201] 8-(6-(3-(2-azaspiro[3.4]octan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; and

[0202] 8-(6-(3-(6-azabicyclo[3.2.0]heptane-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one.

[0203] Exemplary compounds of formula (I) are listed in Table 1 below.

[0204] Table 1

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214] The compounds provided herein are described with reference to general formulae and specific compounds. In addition, the compounds of the present disclosure may exist in a variety of different forms or derivatives, all of which are within the scope of the present disclosure. These include, for example, tautomers, stereoisomers, racemic mixtures, regioisomers, salts, prodrugs, solvated forms, different crystal forms or polymorphs, and active metabolites.

[0215] The compounds of the present disclosure may contain one or more asymmetric centers and therefore may exist in various stereoisomeric forms, such as enantiomers and / or diastereomers. Therefore, the compounds of the present invention and compositions thereof may be in the form of individual enantiomers, diastereomers or geometric isomers, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the present disclosure are enantiomerically pure compounds. In certain embodiments, a mixture of enantiomers or diastereomers is provided.

[0216] The term "enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other. The term "diastereomers" refers to a pair of optical isomers that are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity.

[0217] In addition, unless otherwise specified, certain compounds described herein may have one or more double bonds, which may exist as Z or E isomers. The present disclosure further encompasses such compounds as individual isomers substantially free of other isomers, or as mixtures of various isomers, such as racemic mixtures of enantiomers. In addition to the above compounds themselves, the present disclosure also encompasses compositions comprising one or more compounds.

[0218] As used herein, the term "isomer" includes any and all geometric isomers and stereoisomers. For example, "isomers" include cis and trans isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, falling within the scope of the present invention. For example, in some embodiments, a stereoisomer can be provided that is substantially free of one or more corresponding stereoisomers, and can also be referred to as "stereochemically enriched".

[0219] Where a particular enantiomer is preferred, in some embodiments, it may be provided in a form that is substantially free of the opposite enantiomer, and may also be referred to as "optically enriched". As used herein, "optically enriched" means that the compound consists of a significantly greater proportion of one enantiomer. In certain embodiments, the compound consists of at least about 90% by weight of the preferred enantiomer. In other embodiments, the compound consists of at least about 95%, 98% or 99% by weight of the preferred enantiomer. The preferred enantiomer can be separated from the racemic mixture by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, SH et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

[0220] Compounds of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be mutually converted by low energy barriers. For example, proton tautomers (also referred to as prototropic tautomers) include interconversions performed by proton migration, such as keto-enols, amide-imidic acids, lactams-lactams, imines-enamine isomerizations, and cyclic forms (such as 1H- and 3H-imidazoles, 1H-, 2H- and 4H-1,2,4-triazoles, 1H- and 2H-isoindoles and 1H- and 2H-pyrazoles) in which protons can occupy the positions of two or more heterocyclic systems. Valence tautomers include interconversions performed by the reorganization of some bonded electrons. Tautomers can be in equilibrium or spatially locked into a form by appropriate substitution. Unless otherwise stated, compounds of the disclosure identified by name or structure as a particular tautomeric form are intended to encompass the other tautomeric forms.

[0221] The compounds disclosed herein also include prodrugs, active metabolic derivatives (active metabolites), active intermediates and pharmaceutically acceptable salts thereof.

[0222] As used herein, the term "prodrug" refers to a compound or a pharmaceutically acceptable salt thereof that produces a desired active compound when metabolized or converted by solvolysis under physiological conditions. Prodrugs include, but are not limited to, esters, amides, carbamates, carbonates, ureides, solvates or hydrates of active compounds. Typically, prodrugs are inactive or less active than active compounds, but may provide one or more favorable handling, administration and / or metabolic properties. For example, some prodrugs are esters of active compounds; during metabolism, the ester group is cleaved to produce the active compound. In addition, some prodrugs are enzymatically activated to produce an active compound, or to produce a compound that can be further chemically reacted to produce an active compound. Prodrugs may be converted from a prodrug form to an active form in one step, or may have one or more intermediate forms that may themselves be active or inactive. The preparation and use of prodrugs are discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems", Vol. 14 of the A.C. Symposium Series, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, the entire contents of which are incorporated herein by reference.

[0223] As used herein, the term "metabolite", such as an active metabolite, overlaps with a prodrug as described above. Therefore, such metabolites are pharmacologically active compounds, or compounds that can be further metabolized into pharmacologically active compounds, which are derivatives produced by metabolic processes in the subject. For example, such metabolites may be produced due to oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc. of the administered compound or salt or prodrug. Among them, the active metabolite is a derivative compound of such pharmacological activity. For prodrugs, the prodrug compound is generally inactive or less active than the metabolite. For active metabolites, the parent compound can be an active compound or an inactive prodrug.

[0224] Prodrugs and active metabolites can be identified using routine techniques known in the art. See, for example, Bertolini et al., 1997, J Med Chem 40:2011-2016; Shan et al., J Pharm Sci 86:756-757; Bagshawe, 1995, Drug Dev Res 34:220-230; Wermuth, supra.

[0225] As used herein, the term "active intermediate" refers to an intermediate compound in a synthetic process that exhibits the same or substantially the same biological activity as the final synthesized compound.

[0226] The compounds of the present disclosure may be formulated as or in the form of pharmaceutically acceptable salts. Unless otherwise specified, the compounds provided herein include pharmaceutically acceptable salts of such compounds.

[0227] As used herein, the term "pharmaceutically acceptable" means that the substance or composition is chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the subject to be treated therewith.

[0228] As used herein, unless otherwise indicated, the term "pharmaceutically acceptable salt" includes salts that retain the biological effectiveness of the free acid and base of the specified compound and are not biologically or otherwise undesirable. Expected pharmaceutically acceptable salt forms include, but are not limited to, monosalts, disalts, trisalts, tetrasalts, etc. Pharmaceutically acceptable salts are nontoxic in the amount and concentration in which they are administered. The preparation of such salts can promote pharmacological uses by changing the physical properties of the compound without hindering its physiological effects. Useful changes in physical properties include lowering the melting point to facilitate transmucosal administration, and increasing solubility to facilitate higher concentrations of drug administration.

[0229] Pharmaceutically acceptable salts include acid addition salts, such as sulfate, chloride, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfonate and quinate. Pharmaceutically acceptable salts can be obtained from acids, such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid and quinic acid.

[0230] When an acidic functional group (e.g., carboxylic acid or phenol) is present, pharmaceutically acceptable salts also include base addition salts, such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, tert-butylamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamines, and zinc. For example, see Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Co., Easton, PA, Vol. 2, p. 1457, 1995; "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth, Wiley-VCH, Weinheim, Germany, 2002. Such salts can be prepared using the appropriate corresponding bases.

[0231] Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the compound can be dissolved in a suitable solvent, such as an aqueous solution or water-alcohol solution containing a suitable acid, and then separated by evaporating the solution. Therefore, if the specific compound is a base, the desired pharmaceutically acceptable salt can be prepared by any suitable method available in the art, for example, with an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.) or with an organic acid (e.g., acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidic acid (e.g., glucuronic acid or galacturonic acid), α-hydroxy acid (e.g., citric acid or tartaric acid), amino acid (e.g., aspartic acid or glutamic acid), aromatic acid (e.g., benzoic acid or cinnamic acid), sulfonic acid (e.g., p-toluenesulfonic acid or ethanesulfonic acid), etc.) The free base is treated.

[0232] Similarly, if the particular compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide, etc. Illustrative examples of suitable salts include organic salts derived from amino acids (e.g., L-glycine, L-lysine and L-arginine), ammonia, primary, secondary and tertiary amines, and cyclic amines (e.g., hydroxyethylpyrrolidine, piperidine, morpholine or piperazine), and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

[0233] It will be understood that the compounds of the present disclosure may exist in unsolvated forms, solvated forms (eg, hydrated forms), and solid forms (eg, crystalline or polymorphic forms), and the present disclosure is intended to encompass all such forms.

[0234] As used herein, the term "solvate" or "solvated form" refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of a solvent. Some compounds tend to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate. If the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with one molecule of the substance, in which the water remains in its molecular state as H2O.

[0235] As used herein, the terms "crystalline form", "crystal form", "polymorphic form" and "polymorph" are used interchangeably and refer to a crystal structure in which a compound (or a salt or solvate thereof) can be crystallized in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors may lead to one crystal form being dominant. Crystal polymorphs of a compound can be prepared by crystallization under different conditions.

[0236] The present disclosure is also intended to include all isotopes of atoms in the compounds. Isotopes of atoms include atoms having the same atomic number but different mass numbers. For example, unless otherwise indicated, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, or iodine in the compounds of the present disclosure are also intended to include their isotopes, such as but not limited to 1 H. 2 H. 3 H. 11 C. 12 C. 13 C. 14 C. 14 N. 15 N.16 O. 17 O. 18 O. 31 P. 32 P. 32 S. 33 S. 34 S. 36 S. 17 F. 19 F. 35 Cl, 37 Cl, 79 Br, 81 Br, 127 I and 131 I. In some embodiments, hydrogen includes protium, deuterium, and tritium. In some embodiments, carbon includes 12 C and 13 C.

[0237] Synthesis of compounds

[0238] The synthesis of the compounds provided herein (including pharmaceutically acceptable salts thereof) is described in the synthesis schemes in the examples. The compounds provided herein can be prepared using any known organic synthesis techniques and can be synthesized according to any of many possible synthetic pathways, and therefore, these schemes are only illustrative and do not mean to limit other possible methods that can be used to prepare the compounds provided herein. In addition, the steps in the scheme are for better explanation and can be appropriately changed. The embodiments of the compounds in the examples are synthesized for the purpose of research and possible submission to regulatory agencies.

[0239] The reaction of the compound of the present disclosure can be carried out in a suitable solvent, which can be easily selected by the technician in the field of organic synthesis. Suitable solvent can be under the temperature (for example, the temperature range can be from the freezing point of the solvent to the boiling point of the solvent) of the reaction, and is basically unreactive with raw materials (reactants), intermediates or products. Specific reaction can be carried out in a mixture of a solvent or multiple solvents. According to specific reactions steps, those skilled in the art can select a suitable solvent for a specific reaction step.

[0240] The preparation of compounds of the present disclosure may involve the protection and deprotection of various chemical groups. Those skilled in the art can easily determine the need for protection and deprotection and select suitable protecting groups. The chemical properties of protecting groups can be found in, for example, TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

[0241] The reaction can be monitored by any suitable method known in the art. For example, the formation of the product can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-Vis), mass spectrometry, or chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS) or thin layer chromatography (TLC). Those skilled in the art can purify compounds by a variety of methods, including high performance liquid chromatography (HPLC) ("Preparative LC-MS Purification: Improved Compound Specific Method Optimization" Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6 (6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica gel chromatography.

[0242] The structures of the compounds in the examples were characterized by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in units of 10-6 (ppm). Tetramethylsilane (TMS) was used as a reference standard (0.0 ppm) and the concentrations of CDCl3, CD3OD or DMSO-d6 solutions (reported in ppm) were recorded on a Varian instrument (400 MHz). 1 H-NMR spectrum.

[0243] MS measurements were performed using a Shimadzu 2010 mass spectrometer, Agilent 6110A MSD, or 1969A TOF mass spectrometer, employing electrospray, chemical, and electron impact ionization methods for a variety of instruments.

[0244] TLC measurements were performed using Yantai Huanghai HSGF254 silica gel or Anhui Liangchen Silicon Source Plate. The silica gel plate used for TLC was 0.15 mm-0.2 mm. The silica gel plate used for separation and purification of products by TLC was 0.4 mm-0.5 mm.

[0245] Column chromatography was performed on a Biotage system (manufacturer: Dyax Corporation) with a silica gel column or on a silica gel SepPak column (Waters).

[0246] Known starting materials of the present disclosure can be synthesized by using or according to methods known in the art, or can be purchased from commercial suppliers, such as Aldrich Chemical Company, Adamas-beta, TCI or Accela ChemBio Co., Ltd., and used without further purification unless otherwise stated. Tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dichloromethane (DCM), dichloroethane (DCE), dioxane and 1,1,2,2-tetrachloroethane were purchased from Aldrich, they were in Sure sealed bottles and used as received.

[0247] Unless otherwise stated, the reactions of the present disclosure were carried out under a positive pressure of nitrogen or argon or using a drying tube in anhydrous solvents, and the reaction flasks were usually equipped with rubber septa for the introduction of substrates and reagents by syringe. Glassware was oven dried and / or heat dried.

[0248] For the purpose of illustration, the general synthetic route for preparing the compounds of the present disclosure and key intermediates is shown below. For detailed description of each reaction step, see the "Examples" section below. It will be appreciated by those skilled in the art that other synthetic routes can be used to synthesize the compounds of the present invention. Although specific starting materials and reaction reagents are described in the scheme and discussed below, other starting materials and reaction reagents can also be easily replaced to provide a variety of derivatives and / or reaction conditions. In addition, according to the present disclosure, conventional chemical methods well known to those skilled in the art can be used to further modify many compounds prepared by the following methods.

[0249] General synthetic route

[0250] In some embodiments, the compound of formula (I) or a salt thereof can be prepared by reacting a compound of formula (IIa) or formula (IIb):

[0251]

[0252] wherein X is a leaving group (eg, a halogen atom such as a fluorine atom) of a compound having formula (IIIa) or formula (IIIb):

[0253]

[0254] The reaction is conveniently carried out at a suitable temperature (eg a temperature in the range of about 20-100° C.) in a suitable solvent (eg DMF or THF) and in the presence of a base (eg sodium hydride or t-BuOK).

[0255] In some embodiments, the compound of formula (I) can be prepared by reacting a compound of formula (IIa) with formula (IIIc):

[0256]

[0257] Wherein, PG is a suitable protecting group (such as THP), and is cleaved under acidic conditions (such as PTSA), then converted into a good leaving group X (such as mesylate or tosylate), and finally reacted with different amines in the presence of a base (triethylamine or DIEA) to obtain formula (I).

[0258] The compounds of formula (IIa) and formula (IIb) or their salts can be prepared by reacting a compound of formula (IV):

[0259]

[0260] wherein X is a leaving group (eg, a halogen atom such as a chlorine, iodine or bromine atom, or a triflate group) of a compound having formula (Va) or (Vb):

[0261]

[0262] Wherein, X is a leaving group (for example, a halogen atom such as a chlorine, iodine or bromine atom, or a triflate group), and Y is a boronic acid, a boronic ester (for example, a pinacol borate) or a potassium trifluoroborate group. The reaction can be carried out under standard conditions well known to those skilled in the art, for example, in the presence of a palladium source (for example, tetrakis(triphenylphosphine)palladium or palladium(II) acetate), optionally a phosphine ligand (for example, Xantphos or S-phos) and a suitable base (for example, cesium carbonate or triethylamine).

[0263] Compounds of formula (IV) can be prepared by methods analogous to those shown in the Examples section.

[0264] In some embodiments, the compound of formula (I) can also be prepared by reacting a compound of formula (IV) with a compound of formula (VIa) or formula (VIb):

[0265]

[0266] Wherein, Y is boronic acid, boric acid ester (for example, boric acid pinacol ester) or potassium trifluoroborate group.This reaction can be carried out under standard conditions well known to those skilled in the art, for example in the presence of palladium source (for example, tetrakis(triphenylphosphine)palladium or palladium(II) acetate), optionally phosphine ligand (for example, Xantphos or S-phos) and suitable base (for example, cesium carbonate or triethylamine).

[0267] Compounds of formula (VIa) or formula (VIb) can be prepared by methods analogous to those shown in the Examples section.

[0268] Uses of Compounds

[0269] In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof that exhibits ATM kinase inhibitory activity.

[0270] As used herein, the term "ATM kinase inhibitory activity" refers to a decrease in ATM kinase activity, directly or indirectly in response to the presence of a compound of formula (I) or a pharmaceutically acceptable salt thereof, relative to the activity of ATM kinase in the absence of a compound of formula (I) or a pharmaceutically acceptable salt thereof. This decrease in activity may be due to a direct interaction of a compound of formula (I) or a pharmaceutically acceptable salt thereof with ATM kinase, or due to an interaction of a compound of formula (I) or a pharmaceutically acceptable salt thereof with one or more other factors that in turn affect the activity of ATM kinase. For example, a compound of formula (I) or a pharmaceutically acceptable salt thereof may reduce ATM kinase by directly binding to ATM kinase, by causing (directly or indirectly) another factor to reduce the activity of ATM kinase, or by (directly or indirectly) reducing the amount of ATM kinase present in a cell or organism.

[0271] In some embodiments, the compounds of the present disclosure are selective inhibitors of ATM kinase.

[0272] As used herein, the term "selective inhibitor" or "selective inhibition" refers to a provided compound that inhibits ATM kinase in at least one assay described herein (e.g., a biochemical or cellular assay). In some embodiments, the term "selective inhibitor" or "selective inhibition" refers to an inhibition of ATM kinase with an IC 50 In contrast, the provided compounds inhibit enzymes in the PIKK family closely related to ATM kinase (e.g., PI3K, mTOR, and ATR) with IC 50 At least 5000 times higher, at least 4000 times higher, at least 3000 times higher, at least 2000 times higher, at least 1000 times higher, at least 500 times higher, at least 400 times higher, at least 300 times higher, at least 200 times higher, at least 100 times higher, at least 90 times higher, at least 80 times higher, at least 70 times higher, at least 60 times higher, at least 50 times higher, at least 40 times higher, at least 30 times higher, at least 20 times higher, at least 10 times higher.

[0273] In some embodiments, the compounds of the present disclosure are not AO substrates as determined in human liver cytosol.

[0274] As used herein, the term "AO substrate" refers to a given compound that is susceptible to oxidation by aldehyde oxidase ("AO") and is therefore highly susceptible to AO-mediated clearance. In some embodiments, the intrinsic clearance rate (CL) in the human liver cytosol system can be determined. int ) to assess the AO sensitivity of compounds (Zientek M. et al., Drug Metab Dispos, 2010, 1322-27), as described in detail in the Examples section below. Human liver cytosol systems that can be used for assessment are commercially available, for example, from Xenotech, catalog number H0606.C (AX), batch number 1710130. Typically, human liver cytosol extracts can be prepared by ultracentrifugation of liver homogenates obtained from human donors. In certain embodiments, human liver cytosol extracts (e.g., H0606.C (AX) from Xenotech) can be prepared specifically from donors with high AO activity to minimize underestimation of AO-mediated clearance. In some embodiments, PF-04217903 (2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyrazin-5-yl]pyrazol-1-yl]ethanol, reported as a weak AO substrate) and Zaleplon (N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide, considered a strong AO substrate) are used as references in the human liver cytosol system. In certain embodiments, if a compound shows CL int Lower CL than PF-04217903 int (1.8 μL / min / mg protein), the compound would not be considered an AO substrate if the compound showed CL int Higher CL than Zaleplon int (3.1 μL / min / mg protein), the compound is considered to be a strong AO substrate, where CL int The determination was made by the AO analysis described in the AO analysis described in the Examples section below.

[0275] In some embodiments, the compounds of the present disclosure show low AO sensitivity, CL in human hepatocytes intless than about 1.8 μL / min / mg protein, 1.7 μL / min / mg protein, 1.6 μL / min / mg protein, 1.5 μL / min / mg protein, 1.4 μL / min / mg protein, 1.3 μL / min / mg protein, 1.2 μL / min / mg protein, 1.1 μL / min / mg protein, 1 μL / min / mg protein, 0.9 μL / min / mg protein, 0.8 μL / min / mg protein, 0.7 μL / min / mg protein, 0.6 μL / min / mg protein, 0.5 μL / min / mg protein, 0.4 μL / min / mg protein, 0.3 μL / min / mg protein, 0.2 μL / min / mg protein or 0.1 μL / min / mg protein.

[0276] AO is a cytosolic molybdo-flavoenzyme, a class of proteins that require flavin adenine dinucleotide (FAD) and molybdo-xanthine [molybdenum cofactor (MoCo)] for catalytic activity. AO oxidizes aromatic aldehydes to the corresponding carboxylic acids and oxidizes heterocycles to hydroxylated derivatives. The potential of AO to oxidize heterocycles is particularly important in the context of drug design and development because these chemical groups are common synthetic blocks in medicinal chemistry. AO-mediated metabolism is often overlooked during the drug discovery phase, and high clearance issues are not discovered until Phase 1 clinical trials. AO is a cytosolic enzyme, so its potential role in the metabolic clearance of new compounds is not addressed in standard metabolic stability screening using liver microsomes. Hepatocytes are a whole-cell system that contains both microsomes and cytosol. However, AO is an unstable protein and loses a large amount of activity during hepatocyte preparation (Hutzler, JM et al., Drug Metab Dispos, 2014, 1090-7). In vivo studies of AO-mediated metabolism in animal models are also very problematic because the composition of liver AO is different in humans and popular laboratory animals (Garattini, E. et al., Expert Opin Drug Discovery, 2013, 641-54). Human liver is characterized by a single and active AO isozyme, AOX1. The main AOX form expressed in many mouse and rat strains is AOX3. Two other laboratory animals, cats and dogs, are characterized by the absence of AO enzyme activity. AO activity is more active in higher primates (humans and monkeys) than in rodents. AO is highly concentrated in the liver, where it oxidizes a variety of aldehydes and nitrogen-containing heterocyclic compounds, such as anticancer drugs and immunosuppressants (e.g., see Gordon AH, Green DE, Subrahmanyan, "Liver aldehyde oxidase", The Biochemical Journal. 1940, 34(5): 764-74). Human liver cytosol extracts containing AO but without significant amounts of contaminating CYP450s have been shown to be a valuable tool for predicting in vivo clearance mediated by human AO. Human liver cytosol purchased from Xenotech was used immediately after thawing and could not be reused because AO is an unstable enzyme and rapidly inactivated after freeze-thaw. Given the highly variable AO activity, a high-activity batch of human liver cytosol was selected for AO analysis to minimize underestimation of clearance. Reference compounds Zaleplon (high AO clearance) and PF-04217903 (low AO clearance) were used as controls in the AO analysis.

[0277] Without wishing to be bound by any particular theory, it is believed that AO has a significant effect on pharmacokinetics. Due to its broad substrate specificity, AO is able to oxidize many drugs in the liver (Strelevitz TJ, Orozco CC, Obach RS. "Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance". Drug Metabolism and Disposition. 2012, 40 (7): 1441-8). AO greatly promotes the liver clearance of drugs and other compounds (Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, Leimkühler S. "The impact of single nucleotide polymorphisms on humanaldehyde oxidase", Drug Metabolism and Disposition. 2012, 40 (5): 856-64). AO-mediated metabolism often leads to high clearance in humans. For compounds with high clearance, small changes in intrinsic clearance due to different enzyme expression levels between patients can cause large changes in bioavailability. Human AOX1 is highly polymorphic, and some inactivating missense and nonsense polymorphic sites have been described in the population (Garattini, E. et al., Expert Opin Drug Discovery, 2012, 487-503; Hartmann, T. et al., Drug Metab Dispos, 2012, 856-64). This polymorphism leads to reduced levels of encoded AOX1 protein and explains individual differences in AOX activity. In addition, many factors may affect AO activity, such as gender, age, smoking, drug use, and disease state. Therefore, compounds with high AO-mediated clearance have greater inter-patient PK variability, which leads to unexpected toxicity in some individuals and unattainable efficacy in other patients (Garattini, E. et al., Expert Opin Drug Discovery, 2013, 641-54; Hutzler, JM et al., Drug Metab Dispos 2014, 1090-7).

[0278] In contrast to the previously reported ATM inhibitors AZD0156 and AZD1390, which are strong AO substrates, the compounds of the present invention surprisingly have low sensitivity to AO oxidation. Thus, in one aspect, the compounds provided herein and their pharmaceutically acceptable salts are not AO substrates and therefore show better PK profiles than compounds that are AO substrates. For example, in humans with different AO activity levels, the compounds provided herein have low PK variability.

[0279] In some embodiments, the compounds of the present invention are not P-glycoprotein (Pgp) substrates, nor are they substrates of ATP-binding cassette subfamily G member 2 (ABCG2 or BCRP). As used herein, the term "Pgp substrate" means that a given compound is easily transported by Pgp to the ileal lumen (in the case where Pgp is distributed in the intestinal epithelium), bile duct (in the case where Pgp is distributed in hepatocytes), urine filtrate (in the case where Pgp is distributed in the cells of the proximal tubules of the kidney), capillaries (in the case where Pgp is distributed in the capillary endothelial cells constituting the blood-brain barrier and the blood-testis barrier), etc. As used herein, the term "BCRP substrate" means that a given compound is prevented by BCRP from being absorbed in the apical membrane of the intestine, the blood-testis barrier, the blood-brain barrier, and the membranes of hematopoietic progenitor cells and other stem cells, especially the blood-brain barrier. Therefore, a compound or a pharmaceutically acceptable salt thereof that exhibits good brain permeability in a subject is provided, which can be used to treat extracranial cancers and metastatic cancers, such as brain metastases.

[0280] In some embodiments, the Pgp and BCRP sensitivity of the compound can be assessed by MDCK-MDR1 Pgp permeability assay and Caco-2 BCRP permeability assay, respectively, as described in detail in the Examples section below. In some embodiments, the compounds of the present disclosure do not show Pgp sensitivity, and the MDCK-Pgp efflux ratio (MDCK-Pgp ER) is less than about 2.5.

[0281] In some embodiments, compounds of the present disclosure are able to cross the blood-brain barrier (BBB) ​​without the need for agents that promote BBB entry.

[0282] In some embodiments, the compounds of the present invention show low hERG inhibition as determined by the hEGR inhibition assay described in detail in the Examples section below. In some embodiments, the compounds of the present disclosure show less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20% hERG inhibition at 10 μM.

[0283] In some embodiments, the compounds of the present disclosure show good solubility in water. In some embodiments, the compounds of the present disclosure show solubility in water greater than 90 μM, greater than 100 μM, greater than 200 μM, greater than 300 μM, greater than 400 μM, greater than 500 μM, greater than 600 μM, greater than 700 μM, greater than 800 μM, greater than 900 μM, or greater than 1000 μM.

[0284] Due to their ATM kinase inhibitory activity (optionally selective ATM kinase inhibitory activity), compounds of formula (I) and pharmaceutically acceptable salts thereof are useful, for example, in the treatment of diseases or medical conditions mediated at least in part by ATM kinase, including cancer.

[0285] As used herein, the term "cancer" is intended to encompass both non-metastatic cancers and metastatic cancers. In this context, treating cancer involves treating both the primary tumor and tumor metastases.

[0286] As used herein, the term "treatment" is intended to have its normal meaning, i.e., to treat a disease so as to relieve one, part or all of its symptoms in whole or in part, or to correct or compensate for the underlying pathology. Unless there is a specific indication to the contrary, the term "treatment" also includes "prevention." The terms "therapeutic" and "therapeutically" should be interpreted accordingly.

[0287] As used herein, the term "prevention" is intended to have its normal meaning and includes primary prevention, which prevents the disease from developing, and secondary prevention, which is when the disease has already developed and the patient is protected, temporarily or permanently, to prevent the disease from exacerbating or worsening, or to prevent the development of new symptoms associated with the disease.

[0288] The term "treat" is used synonymously with "therapy." Similarly, the term "treatment" can be considered "applying therapy," where "therapy" is as defined herein.

[0289] Thus, in one aspect, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.

[0290] In some embodiments, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament.

[0291] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a disease or condition associated with ATM. In some embodiments, the disease or condition associated with ATM is cancer. In some embodiments, the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, head and neck squamous cell carcinoma, breast cancer, hepatocellular carcinoma, small cell lung cancer and non-small cell lung cancer. In some embodiments, the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, head and neck squamous cell carcinoma and lung cancer.

[0292] In some embodiments, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treating Huntington's disease.

[0293] In some embodiments, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating a disease or condition associated with ATM.

[0294] In some embodiments, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating cancer.

[0295] In some embodiments, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating Huntington's disease.

[0296] Pharmaceutical composition

[0297] The present disclosure provides pharmaceutical compositions comprising one or more compounds of the present disclosure or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions comprise one or more compounds of the present disclosure or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient.

[0298] As used herein, a "pharmaceutical composition" is a preparation of a compound of the present disclosure in a form suitable for administration to a subject. In some embodiments, the pharmaceutical composition is in bulk or unit dosage form. The unit dosage form is any of the following multiple forms, including, for example, tablets, capsules, pills, powders, granules, sachets, cachets, lozenges, suspensions, emulsions, solutions, syrups, aerosols (solid or in a liquid medium), sprays, ointments, pastes, creams, lotions, gels, patches, inhalants, or suppositories. The amount of active ingredient (e.g., a preparation of a disclosed compound or a salt, hydrate, solvate, or isomer thereof) in a unit dose composition is a therapeutically effective amount and varies according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to make routine changes to the dosage according to the age and condition of the patient. The dosage also depends on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal administration of the compounds of the invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In some embodiments, the compounds of the present disclosure are mixed under sterile conditions with pharmaceutically acceptable excipients and any preservatives, buffers, or propellants required.

[0299] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and not biologically or otherwise undesirable, and includes excipients that are acceptable for veterinary as well as human pharmaceutical use. "Pharmaceutically acceptable excipient" used in the specification and claims includes one or more such excipients.

[0300] As used herein, the term "therapeutically effective amount" refers to the amount of a pharmaceutical agent used to treat, improve or prevent an established disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The exact effective amount for a subject will depend on the subject's weight, size and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the ability and judgment of the clinician.

[0301] In some embodiments, the pharmaceutical composition can be formulated so that a compound of the present disclosure or a pharmaceutically acceptable salt thereof can be administered at a dose of 0.01-500 mg / kg body weight / day, e.g., 0.05-500 mg / kg body weight / day, 0.1-500 mg / kg body weight / day, 0.1-400 mg / kg body weight / day, 0.1-300 mg / kg body weight / day, 0.1-200 mg / kg body weight / day, 0.1-100 mg / kg body weight / day, 0.1-80 mg / kg body weight / day, 1-100 mg / kg body weight / day or 1-80 mg / kg body weight / day.

[0302] In some embodiments, the pharmaceutical composition comprises one or more compounds of the present disclosure or a pharmaceutically acceptable salt thereof as a first active ingredient, and further comprises a second active ingredient. The second active ingredient can be any anti-tumor agent known in the art, for example, an anti-tumor agent, an anti-angiogenic agent, an immunotherapy, an efficacy enhancer, etc.

[0303] Examples of anti-neoplastic agents include, but are not limited to, DNA alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustards (e.g., ifosfamide), bendamustine, melphalan, chlorambucil, busufen, temozolomide, and nitrosoureas (e.g., carmustine)); antimetabolites (e.g., gemcitabine and antifolates, such as fluoropyrimidines (e.g., 5-fluorouracil and tegafur), raltitrexed, methotrexate, cytarabine, and hydroxyurea); antitumor antibiotics (e.g., anthracyclines, such as doxorubicin, bleomycin, doxorubicin, liposomal doxorubicin, pirarubicin, daunorubicin, valrubicin, epirubicin, idarubicin, mitomycin-C, actinomycin, aclarubicin, and mithramycin); Antimitotic agents (e.g., vinca alkaloids, such as vincristine, vinblastine, vindesine and vinorelbine, and taxanes, such as paclitaxel, taxotere and polokinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, aztreonide, irinotecan, topotecan and camptothecin); inhibitors of DNA repair mechanisms, such as CHK kinase; DNA-dependent protein kinase inhibitors; poly (ADP-ribose) polymerase inhibitors (PARP inhibitors, including olaparib); and Hsp90 inhibitors, such as pamoic acid and safamidis, inhibitors of ATR kinase (e.g., AZD6738); and WEE 1 kinase inhibitors (e.g., AZD1775 / MK-1775).

[0304] Examples of anti-angiogenic agents include those that inhibit the action of vascular endothelial growth factor, such as, but not limited to, the anti-vascular endothelial cell growth factor antibody bevacizumab; VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), sorafenib, vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW786034) and cediranib (AZD2171); compounds such as those disclosed in International Patent Applications WO97 / 22596, WO 97 / 30035, WO97 / 32856 and WO 98 / 13354; and compounds that act by other mechanisms (e.g., linomimide, inhibitors of integrin αvβ3 function and angiostatin), or inhibitors of angiopoietin and its receptors (Tie-1 and Tie-2), PLGF inhibitors, delta-like ligand inhibitors (DLL-4).

[0305] Examples of immunotherapy methods include, but are not limited to, ex vivo and in vivo methods to increase the immunogenicity of a patient's tumor cells, such as transfection with cytokines (e.g., interleukin-2, interleukin-4, or granulocyte macrophage colony-stimulating factor); methods to reduce T cell anergy or regulatory T cell function; methods to enhance T cell responses to tumors, such as blocking antibodies against CTLA4 (e.g., ipilimumab and tremelimumab), B7H1, PD-1 (e.g., BMS-936558 or AMP-514), PD-L1 (e.g., MEDI4736), and CD4+ T cells. 137 agonist antibodies; methods using transfected immune cells (such as cytokine-transfected dendritic cells); methods using cytokine-transfected tumor cell lines, methods using antibodies against tumor-associated antigens and antibodies that deplete target cell types (for example, unconjugated anti-CD20 antibodies (such as rituximab), radiolabeled anti-CD20 antibodies Bexxar and Zevalin, and anti-CD54 antibody Campath); methods using anti-idiotypic antibodies; methods of enhancing natural killer cell function; methods utilizing antibody-toxin conjugates (such as the anti-CD33 antibody Mylotarg); immunotoxins such as moxifloxacin pasudotox; agonists of toll-like receptor 7 or toll-like receptor 9.

[0306] Examples of efficacy enhancers include folinic acid.

[0307] Therefore, in some embodiments, provided herein is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other anti-tumor agent. In some embodiments, there is one additional anti-tumor agent. In some embodiments, there are two additional anti-tumor agents. In some embodiments, there are three or more additional anti-tumor agents.

[0308] In some embodiments, the amount of additional anti-tumor agent present in the compositions of the present disclosure may be no greater than the amount normally administered in a composition comprising the anti-tumor agent as the sole active agent. In certain embodiments, the amount of additional anti-tumor agent in the compositions of the present disclosure typically ranges from about 50% to 100% of the amount normally present in a composition comprising the anti-tumor agent as the sole therapeutically active agent.

[0309] Therefore, in another aspect, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more anti-tumor agents as described above.

[0310] As used herein, the term "combination" refers to simultaneous, separate or sequential administration. In some embodiments, "combination" refers to simultaneous administration. In some embodiments, "combination" refers to separate administration. In some embodiments, "combination" refers to sequential administration. In the case of sequential or separate administration, the delay in administration of the second component should not cause the combination to lose its beneficial effect.

[0311] In another aspect, provided herein is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more anti-tumor agents listed above, and a pharmaceutically acceptable excipient.

[0312] In another aspect, provided herein is a kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more anti-tumor agents listed above.

[0313] In another aspect, there is provided a kit comprising:

[0314] (a) a first unit dosage form of a compound of formula (I) or a pharmaceutically acceptable salt thereof;

[0315] (b) a second unit dosage form of an antineoplastic agent selected from the group consisting of those listed above; and

[0316] (c) a container for containing the first and second unit dosage forms.

[0317] Treatment

[0318] In another aspect, provided herein is a method for treating a disease or condition associated with ATM in a subject in need thereof, due to the selective ATM kinase inhibitory activity, non-AO, non-Pgp and non-BCRP susceptibility and brain penetration ability of the compounds of the present disclosure, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0319] In some embodiments, the disease or condition associated with ATM is cancer. In some embodiments, the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, head and neck squamous cell carcinoma, breast cancer, hepatocellular carcinoma, small cell lung cancer and non-small cell lung cancer. In some embodiments, cancer is a metastatic cancer. In some embodiments, metastatic cancer includes metastases of the central nervous system. In some embodiments, metastases of the central nervous system include brain metastases. In some embodiments, metastases of the central nervous system include leptomeningeal metastases. When cancer spreads to the meninges (the tissue layer covering the brain and spinal cord), "leptomeningeal metastases" will occur. Metastases can be spread to the meninges through the blood, or they can be transferred by brain metastases and carried by the cerebrospinal fluid (CSF) flowing through the meninges.

[0320] In another aspect, provided herein is a method of treating Huntington's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the disclosure.

[0321] As used herein, the term "subject in need thereof" is a subject suffering from a disease or condition associated with ATM (e.g., cancer), or a subject who has an increased risk of suffering from a disease or condition associated with ATM (e.g., cancer) relative to the general population. In the case of cancer, a subject in need thereof may suffer from precancerous symptoms. "Subject" includes warm-blooded animals. In some embodiments, the warm-blooded animal is a human.

[0322] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof that is effective in providing "therapy" or "treatment" of an ATM-related disease or condition in a subject. In the case of cancer, a therapeutically effective amount may cause any observable or measurable change in a subject as described in the definitions of "therapy", "treatment" and "prevention" above. For example, an effective amount may reduce the number of cancer cells or tumor cells; reduce the size of the overall tumor; inhibit or prevent tumor cells from infiltrating surrounding organs, including, for example, soft tissue and bone; inhibit and stop tumor metastasis; inhibit and prevent tumor growth; alleviate one or more symptoms associated with cancer to some extent; reduce morbidity and mortality; improve quality of life; or a combination of these effects. An effective amount may be an amount sufficient to alleviate disease symptoms in response to inhibition of ATM kinase activity. For cancer treatment, in vivo efficacy may be measured, for example, by assessing survival time, time to disease progression (TTP), response rate (RR), response time and / or quality of life. As will be appreciated by those skilled in the art, an effective amount may vary depending on the route of administration, the use of excipients, and co-use with other agents. For example, in the case of using combination therapy, the amount of the compound of formula (I) or pharmaceutically acceptable salt described in this specification and the amount of other pharmaceutically active agents are effective together to treat the targeted disease of the animal patient when used in combination. In this case, if the combined amount is sufficient to reduce the symptoms of the disease in response to the inhibition of ATM activity as described above, it is a "therapeutically effective amount".

[0323] Generally, a "therapeutically effective amount" can be determined by one skilled in the art by, for example, starting from the dosage ranges described in this specification for compounds of formula (I) or pharmaceutically acceptable salts thereof, as well as dosage ranges of other pharmaceutically active compounds approved or otherwise disclosed.

[0324] The methods for treating ATM-related diseases or conditions described in this specification may be used as a monotherapy. As used herein, the term "monotherapy" refers to administering a single active compound or therapeutic compound to a subject in need thereof. In some embodiments, a monotherapy will involve administering a therapeutically effective amount of one of the compounds of the present disclosure or a pharmaceutically acceptable salt thereof to a subject in need of such treatment.

[0325] Depending on the specific disease or condition to be treated, the methods of treating diseases or conditions associated with ATM described herein may include, in addition to the administration of a compound of formula (I), one or more additional therapies, such as conventional surgery, radiotherapy, chemotherapy, or a combination of such additional therapies. As used herein, the term "combination therapy" refers to the administration of a combination of multiple active compounds.

[0326] As part of a multiple dosage regimen, additional therapies, such as additional anti-tumor agents, may be administered separately from the compounds of the present disclosure. Alternatively, these additional therapies may be part of a single dosage form mixed with the compounds of the present disclosure in a single composition.

[0327] In some embodiments, the compounds of the present disclosure may be administered simultaneously, sequentially or separately with conventional surgery, radiation therapy or chemotherapy for treatment.

[0328] Radiation therapy may include one or more of the following: (i) external radiation therapy using electromagnetic radiation and intraoperative radiation therapy using electromagnetic radiation; (ii) internal radiation therapy or brachytherapy; including interstitial radiation therapy or intracavitary radiation therapy; (iii) whole-body radiation therapy, including but not limited to iodine-131 and strontium-89.

[0329] Chemotherapy may include anti-tumor agents known in the art, for example, anti-tumor formation agents, anti-angiogenesis agents, immunotherapy, efficacy enhancers, etc. described in the present specification.

[0330] Thus, in one aspect, provided herein is a method of treating a disease or condition associated with ATM in a subject in need thereof, wherein a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with radiation therapy.

[0331] In some embodiments, the radiation therapy is brain radiation.

[0332] In some embodiments, the disease or condition associated with ATM is cancer. In some embodiments, the cancer is selected from glioblastoma, lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), breast cancer (e.g., triple negative breast cancer), head and neck squamous cell carcinoma, esophageal cancer, cervical cancer, and endometrial cancer. In some embodiments, cancer is glioblastoma. In some embodiments, cancer is metastatic cancer. In some embodiments, metastatic cancer is a metastatic tumor of the central nervous system. In some embodiments, the metastatic tumor of the central nervous system is a brain metastasis.

[0333] In some embodiments, provided herein are methods of treating glioblastoma in a subject in need thereof, wherein a compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with brain radiation.

[0334] In another aspect, provided herein is a method of treating a disease or condition associated with ATM in a subject in need thereof, wherein a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with one or more additional anti-tumor agents.

[0335] In some embodiments, the disease or condition associated with ATM is cancer.In certain embodiments, an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more additional anti-tumor agents are together effective to produce an anti-cancer effect.

[0336] In some embodiments, additional anti-tumor agents include anti-tumor forming agents, anti-angiogenic agents, immunotherapeutics, efficacy enhancers, and the like.

[0337] In some embodiments, the additional anti-tumor agent is selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, and bleomycin.

[0338] Example

[0339] For illustrative purposes, the following examples are included. However, it should be understood that these examples are not intended to limit the present invention and are only intended to propose methods for implementing the present disclosure. Those skilled in the art will recognize that the chemical reactions described can be easily adjusted to prepare many other compounds of the present invention, and alternative methods for preparing the compounds of the present invention are considered to be within the scope of the present invention. For example, the synthesis of non-exemplary compounds according to the present disclosure can be successfully carried out by modifications obvious to those skilled in the art (e.g., by appropriately protecting interfering groups, by utilizing other suitable reaction reagents known in the art other than those described), and / or by conventional modifications to reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be considered to have applicability for preparing other compounds of the present disclosure.

[0340] The following abbreviations are used in the examples:

[0341] <![CDATA[AlCl3]]> Aluminum Chloride aq. Water-based <![CDATA[B2Pin2]]> Bis(pinacol)diboron CDI N,N'-Carbonyldiimidazole <![CDATA[CH2Cl2]]> Dichloromethane conc. concentrate <![CDATA[Cs2CO3]]> Cesium carbonate DCM Dichloromethane DIEA or DIPEA Diisopropylethylamine DMF N,N-Dimethylformamide EDCl 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide <![CDATA[Et3N]]> Triethylamine EtOAc Ethyl acetate <![CDATA[HNO3]]> Nitric acid HOB 1-Hydroxybenzotriazole <![CDATA[H2SO4]]> sulfuric acid hr(s) Hour <![CDATA[K2CO3]]> Potassium carbonate KK Potassium acetate MeCN Acetonitrile MeI Methyl iodide MeOH Methanol MsCl p-Anisylbenzenesulfonyl chloride NaH Sodium hydride <![CDATA[NaHCO3]]> Sodium bicarbonate <![CDATA[NaNO2]]> Sodium Nitrite <![CDATA[Na2SO4]]> Sodium sulfate <![CDATA[Pd(dppf)Cl2]]> [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) PE Petroleum ether <![CDATA[POCl3]]> Phosphorus trichloride PTSA p-Toluenesulfonic acid r.t. Room temperature (about 18-25℃) THF Tetrahydrofuran

[0342] Example 1

[0343] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0344] The compound of Example 1 was prepared according to the synthetic route shown in Scheme 1:

[0345]

[0346] Solution 1

[0347] Step 1: 1-(2-amino-5-bromo-4-fluorophenyl)ethanone (A2)

[0348]

[0349] To BCl3 (590mL, 1M DCM solution, 590mmol) stirred at 0°C, a solution of 4-bromo-3-fluoroaniline (100g, 526mmol) in CHCl2CHCl2 (1L) was added dropwise. MeCN (88mL) and AlCl3 (80g, 590mmol) were then added to the solution in batches. The resulting mixture was stirred at 120°C for 16 hours. After the reaction was cooled, 2N HCl aqueous solution (1.3L) was added dropwise to the mixture at 0°C; the resulting mixture was stirred at 100°C for another 2 hours. The crude mixture was poured into ice water and extracted with DCM (1L×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give the desired product, 1-(2-amino-5-bromo-4-fluorophenyl)ethanone (27g, 22% yield), as a yellow solid. MS: m / z 232[M+H] + .

[0350] Step 2: 6-Bromo-7-fluorocinnolin-4-ol (A3)

[0351]

[0352] To a solution of 1-(2-amino-5-bromo-4-fluorophenyl)ethanone (40 g, 172 mmol) in concentrated HCL (12 g, 172 mmol) and H2O (56 mL) at 0°C, a solution of NaNO2 (12 g, 172 mmol) in water (12 mL) was added dropwise. The resulting mixture was stirred at this temperature for 1 hour and then heated to 65°C for 16 hours. The crude mixture was poured into ice water and the precipitate was collected by filtration. The solid was washed with water and dried in vacuo to give the desired product (33 g, 79% yield) as a yellow solid. MS: m / z 243 [M+H] + .

[0353] Step 3: 6-Bromo-7-fluoro-3-nitrocinnolin-4-ol (A4)

[0354]

[0355] To a solution of 6-bromo-7-fluorocinnolin-4-ol (50 g, 206 mmol) in concentrated HNO3 (167 mL) stirred at 0°C, concentrated H2SO4 (50 mL) was carefully added dropwise over 10 minutes. The resulting mixture was stirred at 60°C for 3 hours. After cooling, the crude mixture was poured into ice water. The precipitate was collected by filtration, washed with water and dried under vacuum to give the desired product (40 g, yield 67%) as a yellow solid. MS: m / z 288 [M+H]+ .

[0356] Step 4: 6-Bromo-4-chloro-7-fluoro-3-nitrocinnoline (A5)

[0357]

[0358] POCl3 (28 g, 180 mmol) was added dropwise to a solution of 6-bromo-7-fluoro-3-nitrocinnoline-4-ol (40 g, 139 mmol) in DMF (200 mL) stirred at 0 ° C. The resulting mixture was stirred at room temperature for 16 hours. The crude mixture was poured into ice water and extracted with EtOAc (300 mL). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to give a crude product (32 g yield, 75%) as a red oil, which was used in the next step without further purification.

[0359] Step 5: 6-Bromo-7-fluoro-N-isopropyl-3-nitrocinnolin-4-amine (A6)

[0360]

[0361] To a solution of 6-bromo-4-chloro-7-fluoro-3-nitrocinnoline (32 g, 104 mmol) and Et3N (31 g, 312 mmol) in DCM (500 mL) stirred at room temperature, isopropylamine (12 g, 208 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. The crude mixture was then concentrated to dryness, and the residue was purified by silica gel column chromatography to give the desired product (30 g, 87% yield) as a yellow solid. MS: m / z 329 [M+H] + .

[0362] Step 6: 6-Bromo-7-fluoro-N4-isopropylcinnoline-3,4-diamine (A7)

[0363]

[0364] To a solution of 6-bromo-7-fluoro-N-isopropyl-3-nitrocinnoline-4-amine (44 g, 134 mmol) in EtOAc (10 mL) stirred at room temperature, SnCl2·2H2O (117 g, 536 mmol) was added. The resulting mixture was stirred at 80°C for 2 hours. The crude mixture was alkalized with aqueous NaHCO3 solution, pH=9 was adjusted, and then filtered. The filtrate was diluted with EtOAc (1 L). The organic phase was washed with water and brine, filtered and concentrated. The residue was purified by silica gel column chromatography to give the desired product (26 g, yield 65%) as a yellow solid. MS: m / z 299 [M+H] + .

[0365] Step 7: 8-Bromo-7-fluoro-1-isopropyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (A8)

[0366]

[0367] To a solution of 6-bromo-7-fluoro-N4-isopropylcinnoline-3,4-diamine (26 g, 87 mmol) in THF (200 mL) stirred at room temperature, CDI (81 g, 500 mmol) was added. The resulting mixture was stirred at 70 ° C for 16 hours. The crude mixture was concentrated and the residue was poured into ice water and extracted with EtOAc (1 L). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give the desired product (21 g, yield 74%) as a yellow solid. MS: m / z 325 [M+H] + .

[0368] Step 8: 8-Bromo-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (A9)

[0369]

[0370] To a solution of 8-bromo-7-fluoro-1-isopropyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (21 g, 64 mmol) in DMF (200 mL) stirred at room temperature, K2CO3 (26 g, 194 mmol) was added. The resulting mixture was stirred at 40°C for 2 hours and then cooled to 0°C. After MeI (22 g, 161 mmol) was added dropwise, the reaction was stirred at room temperature for 2 hours. The crude mixture was then poured into ice water and the precipitate was collected by filtration. The solid was washed with water and dried in vacuo to give the desired product (13 g, 59% yield) as a yellow solid. MS: m / z 339[M+H] + .

[0371] Step 9: 7-Fluoro-8-(6-fluoropyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (A10)

[0372]

[0373] To a mixture of (6-fluoropyridin-3-yl)boronic acid (2g, 15mmol) and 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2-one (5g, 15mmol) in a solution of 1,4-dioxane (100mL) and water (10mL), Na2CO3 (125.4mg, 1.18mmol) was added, followed by Pd(dppf)Cl2 (1.1g, 1.5mmol). The reaction mixture was stirred at 100°C for 16 hours under nitrogen protection. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=50:1) to give the desired product (5g, yield 95%) as a yellow solid. MS: m / z 356[M+H] + .

[0374] Step 10: 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0375]

[0376] At 0°C, t-BuOK (1 g, 9 mmol) was added to a solution of 3-(piperidin-1-yl)propan-1-ol (1 g, 6.8 mmol) in THF (30 mL). After the reaction mixture was stirred at 0°C for 30 minutes, 7-fluoro-8-(6-fluoropyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (1.6 g, 4.5 mmol) was added thereto. The reaction mixture was stirred at room temperature for another hour and then poured into ice water. The resulting mixture was extracted twice with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM: MeOH = 30: 1) to give the desired product (530 mg, yield 25%) as a white solid. MS: 479 [M + H] + . 1H NMR (400MHz, DMSO-d6) δ8.51(t,J=1.9Hz,1H),8.33(d,J=7.8Hz,1H),8.16(d,J=11.5Hz,1H),8.05(d,J=8.7Hz,1H),6.98(d,J=8.6Hz,1H ),5.29-5.19(m,1H),4.36(t,J=6.6Hz,2H),3.57(s,3H),2.48-2.18(m,6H),1.98-1.84(m,2H),1.63(d,J=6.7Hz,6H),1.58-1.32(m,6H).

[0377] The compound of Example 1 was also prepared according to the synthetic route shown in Scheme 2:

[0378]

[0379] Solution 2

[0380] Step 1: 5-Bromo-2-(3-(piperidin-1-yl)propoxy)pyridine (B2)

[0381]

[0382] NaH (2.3 g, 56.8 mmol) was added to a solution of 3-(piperidin-1-yl)propan-1-ol (4 g, 28.4 mmol) in DMF (50 mL) at 0°C, and the reaction mixture was stirred at 0°C for 30 minutes. 5-bromo-2-fluoropyridine (5 g, 28.4 mmol) was then added to the mixture, and the reaction mixture was stirred at room temperature overnight. The mixture was poured into ice water and extracted with EtOAc (200 mL×2). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAC=4:1 to 1:1) to give the product (5.2 g, 61.2% yield) as a brown oil. MS: m / z 299[M+H] + .

[0383] Steps 2 & 3: 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0384]

[0385] To a stirred solution of 5-bromo-2-(3-(piperidin-1-yl)propoxy)pyridine (2.6 g, 8.7 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan-2-yl (2.2 g, 8.7 mmol) and KOAc (2.6 g, 26.1 mmol) in 1,4-dioxane (50 mL) under nitrogen at room temperature was added Pd(dppf)Cl2 (0.7 g, 1.0 mmol) and the resulting mixture was stirred at 90°C overnight under nitrogen and cooled. Under nitrogen, 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2-one (2.9 g, 8.7 mmol), Na2CO3 (9.2 g, 8.7 mmol), H2O (10 mL) and Pd(dppf)Cl2 (640 mg, 0.87 mmol) were added to the above mixture. The resulting mixture was stirred at 100 ° C for 16 hours. After cooling, the crude mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by silica gel chromatography (DCM: MeOH = 30: 1) to give the desired product (1.2 g, yield 29%) as a light yellow solid. The analytical data were consistent with the previous method.

[0386] Example 2

[0387] 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0388]

[0389] According to Scheme 2 in Example 1, the title compound was directly synthesized from 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one to obtain the desired product (yield 17%) as a yellow solid. MS: m / z 439 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.40(s,1H),5.16-5.10(m,2H),7.91(dt,J=8.6,2.3Hz,1H),6.91(d,J=8.6Hz,1H),5.20-5.07( m,1H),4.52(t,J=5.8Hz,2H),3.75(s,3H),3.20-3.14(m,2H),2.81(s,6H),2.43-2.36(m,2H),1.76(d,J=6.9Hz,6H).

[0390] Example 3

[0391] 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0392]

[0393] The title compound was synthesized according to Scheme 1 in Example 1 to give the desired product (yield 41%) as a white solid. MS: m / z 465 [M+H] + . 1 H NMR (400MHz, CD3OD) δ8.45(t,J=2.1Hz,1H),8.31(d,J=7.6Hz,1H),8.10-7.94(m,2H),6.95(d,J=8.6Hz,1H),5.35-5.17(m, 1H), 4.43 (t, J = 6.3Hz, 2H), 3.67 (s, 3H), 2.73-2.53 (m, 6H), 2.14-2.01 (m, 2H), 1.84 (p, J = 3.2Hz, 4H), 1.74 (d, J = 6.8Hz, 6H).

[0394] The title compound was also synthesized according to Scheme 2 in Example 1 to give the desired product (yield 53%) as a white solid whose analytical data were consistent with those obtained above.

[0395] Example 4

[0396] 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0397]

[0398] To a mixture of 7-fluoro-8-(6-fluoropyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (23 mg, 0.06 mmol) and N,N-dimethylpiperidin-4-amine (11.1 mg, 0.09 mmol) in acetonitrile (4 mL) was added Cs2CO3 (75.5 mg, 0.23 mmol) and the reaction mixture was stirred at 100°C overnight. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was purified by preparative TLC (DCM: MeOH = 10: 1) to give the desired product (15 mg, yield 51%) as a yellow solid. MS: m / z 464 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.46(s,1H),8.10(t,J=9.2Hz,2H),7.83(dt,J=8.9,2.4Hz,1H),6.82(d,J=9.0Hz,1H),5.21- 5.06(m,1H),4.60-4.56(m,2H),3.74(s,3H),3.01-2.94(m,3H),2.60(s,6H),2.22-2.19(m,2H),1.76-1.70(m,8H).

[0399] Example 5

[0400] 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0401]

[0402] The title compound was prepared using a method similar to Example 4. MS: m / z 464 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.45 (s, J=2.3Hz, 1H), 8.11-8.07 (m, 2H), 7.80 (dt, J= 8.8,2.6Hz,1H),6.52(d,J=8.9Hz,1H),5.20-5.10(m,1H),3.78-3.69(m,5H) ,3.57-3.52(m,1H),3.29-3.25(m,1H),2.65-2.58(m,1H),2.47-2.45(m,1H ), 2.35 (s, 6H), 2.28-2.20 (m, 1H), 1.86-1.81 (m, 2H), 1.75 (d, J = 7.0Hz, 6H).

[0403] Example 6

[0404] 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0405] The compound of Example 6 was prepared according to the synthetic route shown in Scheme 3.

[0406]

[0407] Solution 3

[0408] Step 1: 2-((5-bromopyridin-2-yl)methoxy)-N,N-dimethylethylamine (C2)

[0409]

[0410] To a solution of 2-(dimethylamino)ethanol (267 mg, 3.0 mmol) in DMF (20 mL) stirred at 0°C under nitrogen, NaH (60%, 120 mg, 3.0 mmol) was added. The resulting mixture was stirred at 0°C for another 30 minutes, and then 5-bromo-2-(chloromethyl)pyridine (300 mg, 1.5 mmol) was added thereto. After stirring at room temperature for 2 hours, the crude mixture was poured into ice water and extracted with EtOAc (10 mL×2). The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered, and then concentrated to give a crude product (350 mg) as a brown oil, which was used in the next step without further purification. MS: m / z 259 [M+H] + .

[0411] Steps 2 & 3: 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0412]

[0413] To a solution of 2-((5-bromopyridin-2-yl)methoxy)-N,N-dimethylethan-1-amine (350 mg, 1.4 mmol), KOAc (392 mg, 4.0 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (343 mg, 1.4 mmol) in 1,4-dioxane (20 mL) stirred at room temperature under nitrogen, Pd(dppf)Cl2 (100 mg, 0.1 mmol) was added. The resulting mixture was stirred at 90°C for 16 hours under nitrogen protection. After the reaction was cooled, 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (475 mg, 1.4 mmol), K2CO3 (276 mg, 2 mmol) and H2O (1 mL) were added, followed by Pd(dppf)Cl2 (100 mg, 0.1 mmol). After stirring at 100°C for 4 hours under nitrogen protection, the crude mixture was cooled, diluted with EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (DCM:MeOH=20:1 to 10:1) to give a crude product, which was further purified by preparative TLC (DCM:MeOH=10:1) to give the desired product (30 mg, 5% yield) as a light yellow solid. MS: m / z 439[M+H] + . 1 H NMR (400MHz, CDCl3) δ8.86 (s, 1H), 8.18 (d, J = 11.1Hz, 3H), 7.62 (s, 1H), 5.15 (s, 1H), 4 .83(s,2H),4.05(t,J=5.0Hz,2H),3.76(s,3H),3.15(s,2H),2.77(s,6H),1.76(s,6H).

[0414] Example 7

[0415] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0416]

[0417] The title compound was prepared using a method similar to Example 6 to give the desired product (yield 5%) as a yellow solid. MS: 479 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.85(s,1H),8.24-8.15(m,2H),8.03(dt,J=8.2,2.2Hz,1H),7.61(d,J=8.1Hz,1H),5.20-5.10(m,1 H), 4.78 (s, 2H), 4.14 (t, J = 4.8Hz, 2H), 3.76 (s, 3H), 3.27-3.04 (m, 6H), 2.01 (s, 4H), 1.76 (d, J = 6.9Hz, 6H), 1.63 (s, 2H).

[0418] Example 8

[0419] 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(pyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0420]

[0421] The title compound was prepared using a method similar to Example 6 to give the desired product (yield 5%) as a yellow solid. MS: 465 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.87(s,1H),8.19(dd,J=9.3,6.7Hz,2H),8.05(dt,J=8.3,2.2Hz,1H),7.65(d,J=8.1Hz,1H),5.24-5.08 (m,1H),4.82(s,2H),4.15(t,J=4.7Hz,2H),3.76(s,3H),3.38(t,J=4.8Hz,6H),2.16(d,J=6.7Hz,4H),1.76(d,J=7.0Hz,6H).

[0422] Example 9

[0423] (R)-7-Fluoro-8-(6-((2-(3-fluoropyrrolidin-1-ylethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0424]

[0425] The title compound was prepared using a method similar to Example 6 to give the desired product (yield 3%) as a yellow solid. MS: 483 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.84(s,1H),8.19(d,J=10.8Hz,2H),8.04(s,1H),7.65(d,J=6.9Hz,1H),5.38-5.06(m, 2H), 4.80 (s, 2H), 3.91 (s, 2H), 3.76 (s, 3H), 3.37-2.89 (m, 6H), 2.19 (d, J = 23.4Hz, 2H), 1.76 (d, J = 7.0Hz, 6H).

[0426] Example 10

[0427] 7-Fluoro-8-(6-((2-(4-fluoropiperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0428]

[0429] The title compound was prepared using a method similar to Example 6 to give the desired product (yield 5%) as a yellow solid. MS: 497 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.84(s,1H),8.25-8.12(m,2H),8.03(dt,J=8.2,2.3Hz,1H),7.63(d,J=8.1Hz,1H),5.22-5.08(m ,1H),4.78(s,3H),3.94(s,2H),3.76(s,3H),2.92(d,J=21.1Hz,6H),2.18(s,2H),2.01(s,2H),1.76(d,J=6.9Hz,6H).

[0430] Embodiment 11

[0431] 8-(6-((2-(3-azabicyclo[3.1.0]hexane-3-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0432]

[0433] The title compound was prepared using a method similar to Example 6 to give the desired product (yield 5%) as a yellow solid. MS: 477 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.85 (s, 1H), 8.21-8.17 (m, 2H), 8.04 (dt, J = 8.1, 2.2Hz, 1H), 7.60 (d, J = 8.1Hz, 1H), 5.23-5.09(m,1H),4.78(s,2H),4.08(s,2H),3.76(s,5H),3.14(d,J=54.5Hz,4H),1.77(d,J=6.9Hz,10H).

[0434] The following compounds were prepared according to the procedures described above using different starting materials.

[0435]

[0436]

[0437] Example 12

[0438] N-(2-(Dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)picolinamide

[0439] The compound of Example 12 was prepared according to the synthetic route shown in Scheme 4:

[0440]

[0441] Solution 4

[0442] Step 1: 5-Bromo-N-(2-(dimethylamino)ethyl)picolinamide (D2)

[0443]

[0444] To a solution of 5-picolinic acid (250 mg, 1.2 mmol) in DMF (20 mL), HOBt (140 mg, 1.2 mmol), EDCI (400 mg, 2 mmol) and DIPEA (330 mg, 3 mmol) were added, and the reaction mixture was stirred at room temperature for 30 minutes. N', N'-dimethylethane-1,2-diamine (170 mg, 2 mmol) was then added to the mixture. The reaction mixture was stirred at room temperature for 12 hours and then poured into ice water. The resulting mixture was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a crude product (250 mg) as a brown oil, which was used in the next step without further purification. MS: m / z 272 [M+H] + .

[0445] Steps 2 & 3: N-(2-(dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)picolinamide

[0446]

[0447] To a solution of 5-bromo-N-(2-(dimethylamino)ethyl)picolinamide (50 mg, 0.2 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (44 mg, 0.2 mmol) in 1,4-dioxane (20 mL) was added KOAc (60 mg, 0.6 mmol) and Pd(dppf)Cl2 (20 mg, 0.02 mmol). The reaction mixture was stirred at 90° C. for 12 h under N2 protection. After the mixture was cooled, water (1 mL), 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnoline-2-one (68 mg, 0.2 mmol), K2CO3 (180 mg, 1 mmol) and Pd(dppf)Cl2 (20 mg, 0.05 mmol) were added to the mixture. The reaction mixture was stirred at 100 ° C for another 4 hours and then filtered. The filtrate was partitioned with EtOAc and water. The separated organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=20:1 to 10:1) to give a crude product, which was further purified by preparative TLC (DCM:MeOH=10:1 to EtOAc:MeOH=1:1) to give the desired product (16 mg, yield 19%) as a light yellow solid. MS: m / z 452[M+H] + . 1 H NMR (400MHz, CDCl3) δ8.84(d,J=1.9Hz,1H),8.53(t,J=5.7Hz,1H),8.35(d,J=8.1Hz,1H),8.22-8.11(m,3H),5. 23-5.05(m,1H),3.76(s,3H),3.71(q,J=6.0Hz,2H),2.76(t,J=6.0Hz,2H),2.45(s,6H),1.76(d,J=7.0Hz,6H).

[0448] Example 13

[0449] 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0450] The compound of Example 13 was prepared according to the synthetic route shown in Scheme 5:

[0451]

[0452] Solution 5

[0453] Step 1: 3-((Tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol (E2)

[0454]

[0455] To a solution of 3-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol (1.9 g, 11.9 mmol) in anhydrous THF (20 mL) stirred at 0 ° C under nitrogen, NaH (477 mg, 11.9 mmol) was added in batches. The resulting mixture was stirred at room temperature for 30 minutes, and then 5-bromo-2-fluoropyridine (1 g, 6 mmol) was added thereto. After stirring at room temperature for 16 hours, the crude mixture was poured into ice water and extracted with EtOAc (50 mL×2). The combined organic phases were washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give the desired product 3-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol (1.2 g, 63% yield). MS: 316[M+H] + .

[0456] Steps 2 & 3: 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (E4)

[0457]

[0458] To a solution of 5-bromo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridine (200 mg, 0.635 mmol), B2Pin2 (194 mg, 0.76 mmol) and KOAc (187 mg, 1.9 mmol) in dioxane (5 mL) stirred at room temperature under nitrogen, Pd(dppf)Cl2.CH2Cl2 (52 mg, 0.064 mol) was added. The resulting mixture was stirred at 80° C. for 16 hours under N2 protection. After the reaction was cooled, 8-bromo-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (215 mg, 0.635 mmol), Pd(dppf)Cl2.CH2Cl2 (52 mg, 0.064 mmol), Na2CO3 (200 mg, 1.9 mmol) and H2O (1 mL) were added. The resulting mixture was stirred at 100 ° C for another 4 hours under N2 protection. The crude mixture was concentrated to dryness and the residue was purified by silica gel column chromatography to give the desired product (280 mg, yield 89%) as a dark solid. MS: 496 [M+H] + .

[0459] Step 4: 7-Fluoro-8-(6-(3-hydroxypropoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one (E5)

[0460]

[0461] To a solution of 7-fluoro-1-isopropyl-3-methyl-8-(6-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (332 mg, 0.67 mmol) in DCM / MeOH (3 mL / 3 mL) stirred at room temperature, PTSA (255 mg, 1.34 mmol) was added. The resulting mixture was stirred at room temperature for 4 hours. The crude mixture was diluted with DCM (20 mL), washed with aqueous NaHCO3 solution, water and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give the desired product (220 mg, 80% yield), which was used in the next step without further purification. LCMS: 412 [M+H] + .

[0462] Step 4: 3-((5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)pyridin-2-yl)oxy)propyl methanesulfonate (E6)

[0463]

[0464] To a solution of 7-fluoro-8-(6-(3-(hydroxypropoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (201 mg, 0.49 mmol) and Et3N (150 mg, 1.47 mmol) in DCM (3 mL) was added MsCl (112 mg, 0.97 mmol) dropwise at 0°C. The resulting mixture was stirred at room temperature for 60 min and then diluted with DCM (15 mL). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to give the crude product (340 mg, 100% yield), which was used in the next step without further purification. MS: 490 [M+H] + .

[0465] Step 5: 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0466]

[0467] To a solution of 3-((5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)pyridin-2-yl)oxy)propyl methanesulfonate (170 mg, 0.32 mmol) and DIEA (206 mg, 1.6 mmol) in MeCN (5 mL) stirred at room temperature, 4-fluoropiperidine (180 mg, 1.28 mmol) was added in one portion. The resulting mixture was stirred at room temperature for 16 hours and then diluted with DCM (20 mL). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative TLC to give the desired product (10 mg, 6% yield) as a yellow solid. MS: 497 [M+H] + . 1H NMR (400MHz, CD3OD) δ8.31(d,J=7.7Hz,1H),8.21(d,J=2.6Hz,1H),8.00(d,J=11.5Hz,1H),7.91(dt,J=9.4,2.3Hz,1H),6.71(d,J=9.4Hz,1H),5.37-5 .21(m,1H),4.79-4.65(m,1H),4.21(t,J=7.0Hz,2H),3.66(s,3H),2.95-2. 62(m,6H),2.14(t,J=7.2Hz,2H),2.08-1.85(m,5H),1.75(d,J=6.8Hz,6H).

[0468] Embodiment 14

[0469] (S)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0470]

[0471] The title compound was prepared using a method similar to Example 13 to give the desired product (yield 20%) as a yellow solid. MS: 482 [M+H] + . 1 H NMR (400MHz, CD3OD) δ8.30(d,J=7.6Hz,1H),8.21(d,J=2.5Hz,1H),7.98(d,J=11.5Hz,1H),7.91(dt,J=9.4,2.3Hz,1H),6.71(d,J=9.4Hz,1H),5.35 -5.19(m,2H),4.22(t,J=7.0Hz,2H),3.66(s,3H),3.23(td,J=12.0,10.1 ,7.2Hz,2H),3.08-2.83(m,4H),2.31-2.09(m,4H),1.75(d,J=6.8Hz,6H).

[0472] Embodiment 15

[0473] (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0474]

[0475] The title compound was prepared using a method similar to Example 13 to give the desired product (yield 21%) as a yellow solid. LCMS: 482 [M+H] + . 1 H NMR (400MHz, CD3OD) δ8.30(d,J=7.7Hz,1H),8.21(d,J=2.6Hz,1H),7.98(d,J=11.5Hz,1H),7.90(dt,J=9.4,2.4Hz,1H),6.70(d,J=9.4Hz,1 H),5.34-5.22(m,2H),4.22(t,J=7.0Hz,2H),3.66(s,3H),3.24-3.12(m,2H),2.99-2.74(m,4H),2.28-2.05(m,4H),1.75(d,J=6.8Hz,6H).

[0476] Example 16

[0477] 8-(6-(3-(3-azabicyclo[3.1.0]hexane-3-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0478]

[0479] The title compound was prepared using a method similar to Example 13 to give the desired product (yield 24%) as a yellow solid. MS: 477 [M+H] + . 1 H NMR (400MHz, CD3OD) δ8.32(d,J=7.6Hz,1H),8.19(d,J=2.6Hz,1H),8.00(d,J =11.5Hz,1H),7.93(dt,J=9.4,2.3Hz,1H),6.73(d,J=9.4Hz,1H),5.29(h,J=6 .7Hz,1H),4.22(t,J=6.9Hz,2H),3.66(s,3H),3.44(d,J=10.5Hz,2H),3.13- 2.98(m,4H),2.24-2.14(m,2H),1.75(d,J=6.8Hz,8H),0.72(t,J=5.0Hz,2H).

[0480] The following compounds were prepared according to the procedures described above using different starting materials.

[0481]

[0482]

[0483] Embodiment 17

[0484] 8-(6-(3-(dimethylamino)propoxy)-2-fluoropyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one

[0485]

[0486] The title compound was prepared using a method similar to Example 1. MS: m / z 457 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.22(d,J=7.2Hz,1H),8.16(d,J=10.8Hz,1H),7.88(ddd,J=10.0,8.4,2.0Hz,1H),6.91-6.74(m,1H),5.27 -5.01(m,1H),4.43(t,J=6.4Hz,2H),3.76(s,3H),2.52(t,J=7.4Hz,2H),2.32(s,6H),2.08-1.98(m,2H),1.75(d,J=7.0Hz,6H).

[0487] Embodiment 18

[0488] 7-Fluoro-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0489] The compound of Example 18 was prepared according to the synthetic route shown in Scheme 6:

[0490]

[0491] Solution 6

[0492] Step 1: 6-Bromo-7-fluoro-3-nitro-N-(tetrahydro-2H-pyran-4-yl)cinnolin-4-amine (F1)

[0493]

[0494] To a solution of 6-bromo-4-chloro-7-fluoro-3-nitrocinnoline (1 g, 3.28 mmol) and Et3N (1.4 mL, 9.8 mmol) in DCM (15 mL) stirred at room temperature, tetrahydro-2H-pyran-4-amine (497 mg, 4.9 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours and concentrated. The residue was purified by silica gel chromatography to give the desired product (800 mg, 65% yield) as a yellow solid. MS: m / z 371 [M+H] + .

[0495] Step 2: 6-Bromo-7-fluoro-N4-(tetrahydro-2H-pyran-4-yl)cinnoline-3,4-diamine (F2)

[0496]

[0497] To a solution of 6-bromo-7-fluoro-3-nitro-N-(tetrahydro-2H-pyran-4-yl)cinnoline-4-amine (900 mg, 2.43 mmol) in EtOAc (20 mL) stirred at room temperature, SnCl2·2H2O (2.2 g, 9.7 mmol) was added. The resulting mixture was stirred at 80°C for 2 hours. The crude mixture was alkalized with aqueous Na2CO3 solution, pH=9 was adjusted, and the precipitate was filtered out. The filtrate was diluted with EtOAc (20 mL), the organic phase was washed with water and brine, filtered and concentrated. The residue was purified by silica gel column chromatography to give the desired product (750 mg, yield 90%) as a yellow solid. MS: m / z 341 [M+H] + .

[0498] Step 3: 8-Bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (F3)

[0499]

[0500] To a solution of 6-bromo-7-fluoro-N4-(tetrahydro-2H-pyran-4-yl)cinnoline-3,4-diamine (900 mg, 2.65 mmol) in THF (20 mL) stirred at room temperature, CDI (2.2 g, 13.3 mmol) was added. The resulting mixture was stirred at 70 ° C for 16 hours and then concentrated. The residue was poured into ice water and the precipitate was collected by filtration. The solid was washed with water and dried in vacuo to give the desired product (800 mg, yield 82%) as a yellow solid. MS: m / z 367 [M+H] + .

[0501] Step 4: 8-Bromo-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (F4)

[0502]

[0503] To a solution of 8-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (800 mg, 2.18 mmol) in DMF (3 mL) stirred at room temperature, K2CO3 (905 mg, 6.56 mmol) was added, and the resulting mixture was stirred at 40°C for 2 hours. The reaction mixture was cooled to 0°C, and MeI (774 mg, 5.45 mmol) was added dropwise thereto. The resulting mixture was stirred at room temperature for another 2 hours and then poured into ice water. The precipitate was collected by filtration, washed with water and dried in vacuo to give the desired product (500 mg, 60% yield) as a yellow solid. MS: m / z 381 [M+H] + .

[0504] Step 5: 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0505]

[0506] To a solution of 8-bromo-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (50 mg, 0.132 mmol), 2-(3-(piperidin-1-yl)propoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (46 mg, 0.132 mmol) and Na2CO3 (42 mg, 0.4 mmol) in dioxane / H2O (2 mL / 0.5 mL) stirred at room temperature under nitrogen, Pd(dppf)Cl2 (11 mg, 0.0132 mmol) was added. The resulting mixture was stirred at 100°C for 16 hours. The crude mixture was then filtered and the filtrate was concentrated. The residue was purified by preparative TLC to give the desired product (18 mg, yield 26%) as a yellow solid. MS: 521 [M+H] + . 1H NMR (400MHz, CDCl3) δ8.44(s,1H),8.26(d,J=7.4Hz,1H),8.17(d,J=11.2Hz,1H),7.93(d,J=8.8Hz,1H),6.90(d,J=8.8Hz,1H),5.02(s,1H),4.51(t ,J=5.8Hz,2H),4.24(m,2H),3.78(s,3H),3.61(t,J=11.8Hz,2H),3.17(t ,J=8.4Hz,2H),2.85-2.70(m,2H),2.51-2.46(m,2H),2.22-1.63(m,12H).

[0507] Embodiment 19

[0508] 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0509]

[0510] The title compound was prepared using a method similar to Example 18. MS: 481 [M+H] +.1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.27(d,J=7.4Hz,1H),8.18(d,J=11.2Hz ,1H),7.93(dt,J=8.7,2.3Hz,1H),6.91(d,J=8.7Hz,1H),5.02(s,1H),4.52 (t,J=5.9Hz,2H),4.24(dd,J=11.9,4.9Hz,2H),3.78(s,3H),3.60(dd,J=12 .9,10.8Hz,2H),3.13(s,2H),2.77(m,8H),2.38(s,2H),1.98-1.91(m,2H).

[0511] Embodiment 20

[0512] 7-Fluoro-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0513]

[0514] The title compound was prepared using a method similar to Example 18. MS: m / z 507 [M+H] + .1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.27(d,J=7.3Hz,1H),8.18(d,J=11.1Hz,1H) ,7.97-7.90(m,1H),6.91(d,J=8.7Hz,1H),5.02(s,1H),4.51(t,J=5.8Hz,2H),4. 24(dd,J=11.8,4.8Hz,2H),3.78(s,3H),3.60(t,J=11.9Hz,2H),3.28(d,J=8.1Hz ,2H),2.80(d,J=11.8Hz,2H),2.52-2.44(m,2H),2.18(s,4H),1.95-1.80(m,6H).

[0515] Embodiment 21

[0516] 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0517]

[0518] The title compound was prepared using a method similar to Example 18. MS: m / z 506 [M+H] +.1 H NMR (400MHz, CDCl3) δ8.49(t,J=1.8Hz,1H),8.19(d,J=7.5Hz,1H),8.11(d,J=11.4Hz,1H),7.8 0(dt,J=8.9,2.4Hz,1H),6.54(d,J=8.9Hz,1H),4.99(s,1H),4.24(dd,J=11.8,4.8Hz,2H),3.7 6(s,5H),3.63-3.50(m,3H),3.27(dd,J=10.4,7.2Hz,1H),2.83(d,J=14.1Hz,2H),2.61(p,J=7 .4Hz,1H),2.46(s,1H),2.35(s,6H),2.29-2.18(m,1H),1.94-1.89(m,2H),1.85-1.80(m,2H).

[0519] Embodiment 22

[0520] 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0521]

[0522] The title compound was prepared using a method similar to Example 18. MS: m / z 506 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.51(s,1H),8.24(d,J=7.4Hz,1H),8.14(d,J=11.4Hz,1H),7.86( dt,J=8.9,2.4Hz,1H),6.83(d,J=9.0Hz,1H),5.04-5.01(m,1H),4.64-4.61(m,2H),4.2 7-4.23(m,2H),3.77(s,3H),4.64-3.58(m,2H),3.12-3.08(m,1H),3.01-2.95(m,2H),2 .83-2.80(m,2H),2.67(s,6H),2.27-2.23(m,2H),1.95-1.92(m,2H),1.78-1.74(m,2H).

[0523] Embodiment 23

[0524] 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0525]

[0526] The title compound was prepared using a method similar to Example 18. MS: m / z 481 [M+H] +.1 H NMR (400MHz, CDCl3) δ8.86(s,1H),8.34(d,J=7.3Hz,1H),8.20(d,J=11.1Hz,1H),8.06(s,1H),7.63(s,1H),5.00(s,1H),4.79(s,2H),4.24-4.20( m,2H),3.97(t,J=5.3Hz,2H),3.77(s,3H),3.63-3.59(m,2H),3.03(t,J= 5.2Hz, 2H), 2.83-2.79 (d, J = 14.0Hz, 2H), 2.65 (s, 6H), 1.96-1.91 (m, 2H).

[0527] Embodiment 24

[0528] 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0529] The compound of Example 24 was prepared according to the synthetic route shown in Scheme 7:

[0530]

[0531] Solution 7

[0532] Step 1: 7-Fluoro-3-methyl-8-(6-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (G1)

[0533] To a solution of 5-bromo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridine (200 mg, 0.635 mmol), B2Pin2 (194 mg, 0.76 mmol) and KOAc (187 mg, 1.9 mmol) in dioxane (5 mL) stirred at room temperature under nitrogen was added Pd(dppf)Cl2.CH2Cl2 (52 mg, 0.064 mol). The resulting mixture was stirred at 100° C. under N2 for 16 hours. After the reaction was cooled, 8-bromo-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one (241 mg, 0.635 mmol), Pd(dppf)Cl2.CH2Cl2 (52 mg, 0.064 mmol), Na2CO3 (200 mg, 1.9 mmol) and H2O (1 mL) were added. Under nitrogen protection, the resulting mixture was stirred at 100 ° C for another 4 hours and then concentrated to dryness. The residue was purified by silica gel column chromatography to give the desired product (320 mg, yield 94%) as a dark solid. MS: 538 [M+H] + .

[0534] Step 2: 7-Fluoro-8-(6-(3-hydroxypropoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (G2)

[0535]

[0536] To a solution of 7-fluoro-3-methyl-8-(6-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (360 mg, 0.67 mmol) in DCM / MeOH (3 mL / 3 mL) stirred at room temperature, PTSA (255 mg, 1.34 mmol) was added. The resulting mixture was stirred at room temperature for 4 hours and diluted with DCM (20 mL). The mixture was washed with aqueous Na2SO4, water and brine, dried over anhydrous Na2HCO3, filtered and concentrated to give the desired product (220 mg, 72% yield), which was used in the next step without further purification. MS: 454 [M+H] + .

[0537] Step 3: 3-((5-(7-fluoro-3-methyl-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)pyridin-2-yl)oxy)propyl methanesulfonate (G3)

[0538]

[0539] To a solution of 7-fluoro-8-(6-(3-hydroxypropoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (220 mg, 0.49 mmol) and Et3N (150 mg, 1.47 mmol) in DCM (3 mL) was added MsCl (112 mg, 0.97 mmol) dropwise at 0°C. The resulting mixture was stirred at room temperature for 1 hour and diluted with DCM (15 mL). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to give the crude product (340 mg, 100% yield), which was used in the next step without further purification. MS: 532 [M+H] + .

[0540] Step 4: 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0541]

[0542] To a solution of 3-((5-(7-fluoro-3-methyl-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)pyridin-2-yl)oxy)propyl methanesulfonate (170 mg, 0.32 mmol) and DIEA (206 mg, 1.6 mmol) in MeCN (5 mL) stirred at room temperature, 4-fluoropiperidine (180 mg, 1.28 mmol) was added in one portion. The resulting mixture was stirred at room temperature for 16 hours and diluted with DCM (20 mL). The organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative TLC to give the desired product (42 mg, 24% yield) as a yellow solid. MS: 539[M+H] + . 1 H NMR (400MHz, CD3OD) δ8.42(d,J=7.6Hz,1H),8.23(d,J=2.5Hz,1H),8.05(d,J=11.6Hz,1H),7.97(dt,J=9.5,2.4Hz,1H),6.73(d,J=9.4Hz,1H),5.19 -5.08(m,1H),4.80-4.61(m,1H),4.22-4.15(m,4H),3.75-3.68(m,5H),2. 82-2.75(m,4H),2.74-2.66(m,4H),2.25-2.12(m,2H),2.10-1.85(m,6H).

[0543] Embodiment 25

[0544] (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one

[0545]

[0546] This material was synthesized from (R)-3-fluoropyrrolidine using a method similar to Example 24 to give the desired product (yield 14%) as a yellow solid. MS: 525 [M+H] +.1H NMR (400MHz, CDCl3) δ8.30(s,1H),8.14(d,J=11.8Hz,1H),7.98(s,1H),7.74(d,J=9.6Hz,1H),6.72(d,J=9.6Hz,1H),5.21-5 .07(m,2H),4.29-4.14(m,4H),3.78(s,3H),3.63(t,J=12.0Hz,2H),2.98-2.89(m,2H),2.78-2.62(m,4H),2.18-1.87(m,8H).

[0547] Embodiment 26

[0548] Bioassay

[0549] The efficacy of the compounds disclosed herein can be determined by many pharmacological assays known in the art. The compounds of the present invention and the control compound 8-[6-(3-dimethylamino-propoxy)-pyridin-3-yl]-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]cinnolin-2(3H)-one (reference compound 1) were used to perform the following exemplary pharmacological assays: a) ATM biochemical potency assay; b) PI3K biochemical potency assay; c) mTOR biochemical potency assay; d) ATR biochemical potency assay; and e) ATM SN-38HT-29 cell potency assay. In the description of the assay, generally:

[0550] i. The following abbreviations are used: 4NQO = 4-nitroquinoline N-oxide; Ab = antibody; BSA = bovine serum albumin; CO2 = carbon dioxide; DMEM = Dulbecco's modified Eagle's medium; DMSO = dimethyl sulfoxide; EDTA = ethylenediaminetetraacetic acid; EGTA = ethylene glycol tetraacetic acid; ELISA = enzyme-linked immunosorbent assay; EMEM = Eagle's minimum essential medium; FBS = fetal bovine serum; h = hour; HRP = horseradish peroxidase; ip = intraperitoneal; PBS = phosphate-buffered saline; PBST = phosphate-buffered saline / Tween; TRIS = tris(hydroxymethyl)aminomethane; MTS reagent: [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, and electron coupling agent (phenazine methylsulfate) PMS; sc = subcutaneous.

[0551] ii. Calculate IC using the smart fitting model in Genedata 50 Value. IC 50 Values ​​are the concentrations of test compounds that inhibit 50% of the biological activity.

[0552] Determination a): ATM biochemical potency

[0553] ATM (Millipore, catalog number 14-933) enzyme solution was prepared in 1× kinase alkaline buffer. 10 μl of 2× enzyme solution was transferred to each well of a 384-well assay plate containing 100 nl of compound added by Echo. The plate was incubated at room temperature for 10 minutes. 2× peptide solution (final concentration: 1.5 nM) was prepared with FAM-labeled peptide and ATP in 1× kinase basic buffer. 10 μl of 2× peptide solution was added to each well of a 384-well assay plate, incubated at 37°C for 210 minutes, and then 40 μl of stop buffer was added to terminate the reaction. Data was collected by Caliper.

[0554] Determination b): ATR biochemical efficacy

[0555] ATR enzyme was produced by ChemPartner (Batch: CP-ATR-20161102-M2). 2× enzyme solution was prepared in 1× kinase base buffer. 10 μl of 2× enzyme solution (final concentration: 2.5 nM) was added to each well of a 384-well assay plate containing 60 nl of compound in each well. The plate was incubated at room temperature for 10 minutes. 2× peptide solution was prepared with FAM-labeled peptide and ATP in 1× kinase base buffer. 10 μl of 2× peptide solution was added to each well of a 384-well assay plate and incubated at 28°C for 240 minutes. 40 μl of stop buffer was added to terminate the reaction. Data were collected by Caliper.

[0556] Determination c): PI3K biochemical potency

[0557] Prepare PI3Kα (p110α / p85a), PIK3Cδ, PIK3Cβ (p110β), PIK3Cγ (pp110γ) kinase reaction solutions of PI3Kα (Invitrogen, Cat. No. PV4788), PIK3Cδ (Invitrogen, Cat. No. PV6452), PIK3Cβ (Millipore, Cat. No. 14-603-K), PIK3Cγ (Invitrogen, Cat. No. PR8641C) enzymes in 1× kinase buffer at four times the final concentration of each reagent in the assay (final concentrations: PI3Kα 0.7 nM, PIK3Cδ 3 nM, PIK3Cβ 4.8 nM, PIK3Cγ 11 nM). Add 2.5 μl of kinase solution to each well of a 384-well assay plate containing 2.5 μl of serially diluted concentrations of compound. Prepare 2× substrate solution with PIP2 substrate and ATP in 1× kinase reaction buffer at a concentration of 2 times the final concentration of each reagent in the assay. Add 5μl of substrate solution to each well of the assay plate to start the reaction. Incubate the assay plate at room temperature for 1 hour. Transfer 5μl of the reaction mixture to a new 384-well plate. Add 5μl of ADP-Glo ​​reagent (Promega, Cat. No. v9102 / 3, Batch No. 0000176563) to each well of the new assay plate to terminate the reaction. The plate was shaken slowly and equilibrated for 40 minutes. Add 10μl of kinase detection reagent to each well, equilibrate it for 60 minutes, and then read for luminescence on a plate reader (Envision).

[0558] Determination d): mTOR biochemical efficacy

[0559] Prepare a solution of mTOR enzyme (Millipore, catalog number 14-770, batch number 2052551) in 1× kinase buffer at a concentration of 4 times the final concentration in the assay (final concentration: 6nM). Add 2.5μl of kinase solution to each well of a 384-well assay plate, containing 2.5μl of serially diluted compounds. Prepare 2× substrate solution in 1× kinase reaction buffer with ULight-4E-BP1 (Thr37 / 46) peptide (PE, catalog number TRF0128-M, batch number 1695274) and ATP at a concentration of 2 times the final concentration of each reagent in the assay. Add 5μl of substrate solution to each well of the assay plate to start the reaction. Incubate the assay plate at room temperature for 30 minutes. Prepare a detection solution of kinase quenching buffer (EDTA) and Eu-anti-phospho-4E-BP1 antibody (Thr37 / 46) (PE, catalog number TRF0216-M, lot number 1571838) at a concentration of 2 times the desired final concentration of each reagent in Lance detection buffer. Add 10 μl of detection solution buffer to each well of the assay plate. The assay plate is equilibrated at room temperature for 60 minutes and then read on a plate reader (Lance signal (665 nm) from the Envision program).

[0560] Determination e): ATM SN-38 BT-29 cell efficacy

[0561] Basic principle:

[0562] SN38 is an active metabolite of irinotecan (a topoisomerase-I inhibitor). SN38 causes single-strand DNA breaks (SSBs) that are converted to double-strand breaks (DSBs) during replication. ATM plays a role in repairing DSBs. The inhibition of ATM in SN38-treated HT-29 cells (ATCC, catalog number HTB-38) was evaluated by high-content imaging system.

[0563] Experimental details:

[0564] HT-29 cells were trypsinized, and approximately 10,000 cells were seeded into each well of a 96-well microplate and incubated overnight at 37°C and 5% CO2. The test compound was added to the 96-well plate and incubated for 1 hour at 37°C and 5% CO2. SN38 (MCE, catalog number HY-13704) was then added to the 96-well plate at a final concentration of 30 nM and incubated for 1 hour at 37°C and 5% CO2. After removing the culture medium, the cells were fixed by adding 50 μl of 3.7% formaldehyde in PBSA solution and incubated at room temperature for 20 minutes. After rinsing the plate with PBSA three times, 50 μl of permeabilization buffer (0.1% Triton-X 100 in PBSA) was added, and the plate was incubated at room temperature for 20 minutes. After rinsing the plate with PBSA, 50 μl of primary antibody solution was added, and the plate was incubated overnight at 4°C. The primary antibody solution was prepared by diluting the primary antibody (anti-phospho-ATM (Ser1981) antibody, Merck Millipore, catalog number 05-740) at 1 / 10,000th in antibody buffer (3% BSA, 0.05% Tween in PBSA). The plate was rinsed 3 times with PBST (0.05% Tween in PBSA). 50 μl of secondary antibody solution was added to the plate and the plate was incubated at room temperature in the dark for 1 hour. The secondary antibody solution was prepared by diluting the secondary antibody (goat anti-mouse IgG (H+L) cross-adsorbed secondary antibody, Alexa FluoR488, Invitrogen, catalog number #A11001) at 1 / 500th in antibody buffer, Hoechst 1 / 10,000th. The plate was rinsed 3 times with PBST and then 100 μl PBSA was added to each well. The plate was sealed with a black plate sealer.

[0565] Data Scraping

[0566]

[0567] Data analysis

[0568]

[0569] After image analysis, further statistics were performed using Excel 2013 (Microsoft), and graphical views were generated using Prism 7.0 (Graphpad).

[0570] As described above, the compounds synthesized in Examples 1-45 and Reference Compound 1 were tested in assays a) to e). The IC values ​​of some exemplary compounds are provided in Table 2. 50Results. It can be found from Table 2 that the compounds disclosed in the present invention not only have very good ATM kinase inhibition, but also have high selectivity for ATM kinase relative to other kinases in the PIKK family (PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, mTor and ATR). For other example compounds whose results are not shown, the IC values ​​of all compounds for ATM kinase are 50 None of them exceeded 1000nM. Some of these compounds have IC 50 The values ​​do not exceed 500nM, some do not exceed 400nM, some do not exceed 300nM, some do not exceed 200nM, or do not exceed 100nM, or even do not exceed 50nM. In addition, some example compounds that do not show the results show IC values ​​for other kinases in the PIKK family (PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, mTor and ATR). 50 Greater than 1 μM, some greater than 3 μM, greater than 5 μM, greater than 7 μM or even greater than 10 μM.

[0571] Table 2: Potency data of representative compounds of Examples 1-16 in assays a)-e)

[0572]

[0573] Embodiment 27

[0574] DMPK and hERG inhibition studies

[0575] DMPK and hERG inhibition studies were performed with compounds of the present disclosure as well as Reference Compound 1, Reference Compound 2 (AZD0156) and Reference Compound 3 (AZD1390) using the following assays: f): MDCK-MDR1 Pgp assessment, g) caco-2 BCRP assessment, and h) hERG inhibition assessment.

[0576] Assay f): MDCK-MDR1 Pgp assessment

[0577] Efflux transport mediated by P-glycoprotein (Pgp) was assessed by MDCK-MDR1 cells. The final concentration of the test and control compounds was 1 μM. The multiwell inserts were incubated at 37° C. for 2 hours.

[0578] Measurement g): Caco-2 BCRP assessment

[0579] Caco-2 cells were used to study BCRP-mediated efflux transport. The ratio of drugs transported by BCRP was determined in the presence and absence of neomycin (a powerful BCRP inhibitor), which was added to the apical and basolateral compartments at a final concentration of 30 μM. The final concentration of the test compound and control compound was 1 μM. The multi-well insert was incubated at 37°C for 2 hours. Efflux ratios (-inhibitor / +inhibitor)>2 were considered to be BCRP substrates.

[0580] Determination h): hERG safety assessment

[0581] Inhibition of hERG channels was performed by manual patch clamp in a HEK 293 cell line stably expressing the hERG channel.

[0582] Table 3 shows the results of representative compounds of the present invention and reference compounds 1-3 in assays f), g) and h).

[0583] Table 3: Results of representative compounds and reference compounds 1-3 in assays f)-h)

[0584]

[0585] *Not available

[0586] It can be confirmed from Table 3 that reference compound 2 is a Pgp substrate. Reference compound 3 is not a Pgp substrate, but it shows a significant hERG inhibitory effect. In contrast, the representative compounds of Examples 1 and 3-5 are not Pgp substrates and BCRP substrates, indicating that they are brain penetrable. In addition, compared with reference compound 3, the compounds of Examples 1 and 3 show a significant improvement in hERG susceptibility.

[0587] For other example compounds for which no results were shown, all compounds showed DMPK and hERG results similar to those of the exemplary compounds of Examples 1 and 3-5.

[0588] Embodiment 28

[0589] AO activity study

[0590] AO activity studies were performed with compounds of the invention as well as reference compounds 2, 3, 4 (Zaleplon, positive control for AO assay) and 5 (PF-04217903, weak AO substrate) using the following assays: i) Aldehyde oxidase assay.

[0591] Assay i): Aldehyde oxidase assay

[0592] AO activity was evaluated in human liver cytosol. The incubation system consisted of 25 mM phosphate buffer, 1 mg / mL human liver cytosol, and 0.5 μM test compound or positive control. The reaction was stopped at 0.5, 5, 10, 20, 30, and 60 minutes by adding 5 volumes of cold acetonitrile with internal standard. The samples were centrifuged at 3,220 g for 30 minutes. An aliquot of 100 μL of the supernatant was mixed with 100 μL ultrapure H2O and then used for LC / MS / MS analysis.

[0593] All calculations were performed using Microsoft Excel. Peak areas were determined from the extracted ion chromatograms. The slope value k was determined by linear regression of the natural logarithm of the parent drug remaining percentage versus the incubation time curve. The in vitro half-life (in vitro t 1 / 2 ):

[0594] In vitro t1 / 2 = -(0.693 / k).

[0595] The in vitro t 1 / 2 (min) converted to in vitro intrinsic clearance (in vitro CL int , expressed in μL / min / mg protein) (average of replicates):

[0596]

[0597] As described above, the compounds synthesized in Examples 1-25 and the compounds in Reference Compounds 2-4 were tested in assay i). The results for representative compounds of the present disclosure and Reference Compounds 2-5 are shown in Table 4.

[0598] Table 4: Results of representative compounds and reference compounds 2-5 in assay i)

[0599] Example AO intrinsic clearance (μL / min / mg protein) 1 0.84 3 0.29 4 <1 5 <1 6 1.0 7 0.0 8 0.36 9 1.2 10 1.0 11 0.82 13 0.96 15 0.0 23 0.9 Reference compound 2 4.65 Reference compound 3 7.2 Reference compound 4 3.1 Reference compound 5 1.8

[0600] Reference compounds 2 and 3 have been shown to be strong AO substrates, with intrinsic clearances of 4.65 μL / min / mg protein and 7.2 μL / min / mg protein, which are higher than the intrinsic clearance of reference compound 4 (3.1 μL / min / mg protein). Reference compound 4 showed a higher clearance of 16 mL / min / kg in humans, equivalent to about 80% of hepatic blood flow (Zientek, M. et al., Drug Metab Dispos 2010, 1322-7). In contrast, the intrinsic clearance shown by the compounds of the present disclosure was lower than that of reference compound 5 (1.8 μL / min / mg protein). Reference compound 5 showed a low to moderate intrinsic clearance of 6 mL / min / kg in humans, equivalent to about 30% of hepatic blood flow. This indicates that the compounds of the present disclosure are not AO substrates.

[0601] For other example compounds for which no results are shown, all compounds showed intrinsic clearance rates of no more than 2 μL / min / mg protein, no more than 1.8 μL / min / mg protein, no more than 1.6 μL / min / mg protein, no more than 1.4 μL / min / mg protein, no more than 1.2 μL / min / mg protein, no more than 1 μL / min / mg protein, no more than 0.9 μL / min / mg protein, no more than 0.8 μL / min / mg protein, no more than 0.7 μL / min / mg protein, no more than 0.6 μL / min / mg protein, and even no more than 0.5 μL / min / mg protein.

[0602] The foregoing description is considered to be only an illustration of the principles of the present disclosure. In addition, since many modifications and changes are obvious to those skilled in the art, it is not desirable to limit the present invention to the exact construction and method as described above. Therefore, it is considered that all suitable modifications and equivalents fall within the scope of the present invention as defined by the appended claims.

[0603] When used in this specification and the appended claims, the words “comprises” and “comprising” are intended to specify the presence of stated features, integers, components or steps, but they do not exclude the presence or addition of one or more other features, integers, components, steps or groups thereof.

Claims

1. Compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen or methyl; R 2 is isopropyl or tetrahydropyranyl; R 3 It is fluorine; R 4 , R 5 and R 6 are each independently selected from hydrogen or fluorine; R 7 Yes-L-NR 8 R 9 , wherein L is selected from a direct bond, -(CH2) m O(CH2) n -or-CONR 10 (CH2) p -, wherein the -(CH2) m O(CH2) n -and-CONR 10 (CH2) p - optionally one or more R 11 replace; R 8 and R 9 Each independently selected from hydrogen, C 1-6 Alkyl, a saturated or unsaturated cyclic hydrocarbon group containing 3 to 6 ring carbon atoms; or R 8 and R 9 Together with the nitrogen atom to which they are attached, they form a 3- to 12-membered saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S, and is optionally substituted by one or more R 13 replace; R 10 Selected from hydrogen, C 1-6 The group consisting of alkyl, cycloalkyl containing 3 to 6 ring carbon atoms, and carbon-linked 3 to 12-membered saturated or unsaturated heterocyclic radicals, wherein the heterocyclic radicals optionally contain one or more additional heteroatoms selected from N, O and S; R 11 Selected from hydrogen, C 1-6 Alkyl, cycloalkyl containing 3 to 6 ring carbon atoms, C 1-6 Alkoxy; R 13 Selected from C 1-6 Alkyl, cycloalkyl containing 3 to 6 ring carbon atoms, halogen and -(CH2) q NR 14 R 15 The group composed of; R 14 and R 15 Each independently selected from hydrogen, C 1-6 The group consisting of an alkyl group and a cycloalkyl group containing 3 to 6 ring carbon atoms; or R 14 and R 15 Together with the nitrogen atom to which they are attached, they form a 3- to 12-membered saturated or unsaturated heterocyclic group, which optionally contains one or more additional heteroatoms selected from N, O and S; m is 0, 1, or 2; n is an integer from 2 to 4; p is an integer from 2 to 4; and q is 0, 1, or 2.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 1 It's methyl.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 2 It is isopropyl.

4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 4 , R 5 and R 6 It's hydrogen.

5. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 7 Yes-L-NR 8 R 9 , and L is a direct bond.

6. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 5, wherein R 8 and R 9 Each independently selected from C 1-6 alkyl.

7. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 5, wherein R 8 and R 9 Together with the nitrogen atom to which they are attached they form: Each of which is optionally replaced by one or more R 13 wherein x is 1, 2, 3 or 4; y is 0, 1 or 2; and z is 0, 1 or 2.

8. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 7, wherein R 13 It's a halogen.

9. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 7 For-L-NR 8 R 9 , L is a direct key, and R 8 and R 9 Together with the nitrogen atom to which they are attached they form: Each of which is optionally replaced by one or more R 13 wherein x is 1, 2, 3 or 4; y is 0, 1 or 2; and z is 0, 1 or 2.

10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 9, wherein R 13 -(CH2) q NR 14 R 15 , and R 14 and R 15 Each independently selected from C 1-6 alkyl.

11. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 7 For-L-NR 8 R 9 , L is -CONR 10 (CH2) p -, R 8 and R 9 Each independently selected from C 1-6 Alkyl, R 10 For hydrogen.

12. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 1 It is methyl; R 2 is isopropyl; R 3 It is fluorine; R 4 , R 5 and R 6 is hydrogen; R 7 Yes-L-NR 8 R 9 ; L is -(CH2) m O(CH2) n -, which is optionally replaced by one or more R 11 replace; R 8 and R 9 Each independently selected from C 1-6 Alkyl; or R 8 and R 9 Together with the nitrogen atoms to which they are attached, they form Each of which is optionally replaced by one or more R 13 substituted, wherein x is 1, 2, 3 or 4; y is 0, 1 or 2; z is 0, 1 or 2; R 11 It is hydrogen; R 13 It is a halogen; m is 0, 1, or 2; n is an integer from 2 to 4.

13. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein The compound is selected from the group consisting of: 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(pyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; (R)-7-Fluoro-8-(6-((2-(3-fluoropyrrolidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-8-(6-((2-(4-fluoropiperidin-1-yl)ethoxy)methyl)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(3-azabicyclo[3.1.0]hexan-3-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; N-(2-(dimethylamino)ethyl)-5-(7-fluoro-1-isopropyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-8-yl)picolinamide; 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; (S)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(3-azabicyclo[3.1.0]hexane-3-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(dimethylamino)propoxy)-2-fluoropyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(4-(dimethylamino)piperidin-1-yl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(dimethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-8-(6-(3-(4-fluoropiperidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; (R)-7-Fluoro-8-(6-(3-(3-fluoropyrrolidin-1-yl)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(diethylamino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(ethyl(methyl)amino)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-morpholinoethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(piperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-((2-(4-methylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(4-cyclopropylpiperazin-1-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(2-azaspiro[3.3]heptane-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(2-azaspiro[3.4]octan-2-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-((2-(6-azabicyclo[3.2.0]heptane-6-yl)ethoxy)methyl)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(diethylamino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(ethyl(methyl)amino)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-morpholinopropoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(4-methylpiperazin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(4-cyclopropylpiperazin-1-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(2-azaspiro[3.3]heptane-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(2-oxa-6-azaspiro[3.3]heptane-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; 8-(6-(3-(2-azaspiro[3.4]octan-2-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one; and 8-(6-(3-(6-azabicyclo[3.2.0]heptane-6-yl)propoxy)pyridin-3-yl)-7-fluoro-1-isopropyl-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]cinnolin-2-one.

14. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: The intrinsic AO clearance value of the compound in the human liver cytosol system was less than 1.8 μL / min / mg protein.

15. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, and at least one pharmaceutically acceptable excipient.

16. The pharmaceutical composition according to claim 15, wherein The composition does not include an agent for promoting BBB entry.

17. The pharmaceutical composition according to claim 15 or 16, wherein The composition further comprises at least one additional anti-tumor agent selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan and bleomycin.

18. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14 in the preparation of a medicament for treating a disease or condition associated with ATM.

19. The use according to claim 18, wherein The disease or condition associated with ATM is cancer.

20. The use according to claim 19, wherein The cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, head and neck squamous cell carcinoma, breast cancer, hepatocellular carcinoma, small cell lung cancer and non-small cell lung cancer.

21. The use according to claim 19, wherein The cancer is a metastatic cancer.

22. The use according to claim 21, wherein The metastatic cancer is a brain metastasis.

23. The use according to claim 18, wherein The compound of formula (I) or a pharmaceutically acceptable salt thereof is suitable for simultaneous, separate or sequential administration with radiotherapy.

24. The use according to claim 23, wherein The radiation therapy is brain radiation.

25. The use according to claim 23 or 24, wherein The ATM-associated disease or condition is cancer.

26. The use according to claim 25, wherein The cancer is glioblastoma.

27. The use according to claim 18, wherein The compounds are capable of BBB entry in the absence of agents that promote BBB entry.

28. The use according to claim 18, wherein The compound of formula (I) or a pharmaceutically acceptable salt thereof is suitable for simultaneous, separate or sequential administration with at least one additional anti-tumor agent selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan and bleomycin.

29. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14 in the preparation of a medicament for treating Huntington's disease.

30. The use according to claim 29, wherein The compounds are capable of BBB entry in the absence of agents that promote BBB entry.

Citation Information

Patent Citations

  • Quinazoline derivatives

    WO1997022596A1

  • Quinazoline derivatives as VEGF inhibitors

    WO1997030035A1

  • 4-anilinoquinazoline derivatives

    WO1997032856A1

  • Quinazoline derivatives and pharmaceutical compositions containing them

    WO1998013354A1

  • Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

    WO2015170081A1